
(
  (S
    (NP
      (NP (NN Haploinsufficiency))
      (PP (IN for)
        (NP (NN BRCA1))))
    (VP (VBZ is)
      (VP (VBN associated)
        (PP (IN with)
          (NP
            (NP (JJ normal) (NNS levels))
            (PP (IN of)
              (NP
                (NP (NN DNA) (NN nucleotide) (NN excision) (NN repair))
                (PP (IN in)
                  (NP
                    (NP (NN breast) (NN tissue))
                    (CC and)
                    (NP (NN blood) (NNS lymphocytes))))))))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (NP
      (NP (NN Background))
      (: :)
      (S
        (NP (NN Screening) (NN mammography))
        (VP (VBZ has)
          (VP
            (VP (VBD had)
              (NP (DT a) (JJ positive) (NN impact))
              (PP (IN on)
                (NP (NN breast) (NN cancer) (NN mortality))))
            (CC but)
            (VP (MD cannot)
              (VP (VB detect)
                (NP (DT all) (NN breast) (NNS tumors)))))))
      (. .))))

(
  (S
    (S
      (PP (IN In)
        (NP (DT a) (JJ small) (NN study)))
      (, ,)
      (NP (PRP we))
      (VP (VBD confirmed)
        (SBAR (IN that)
          (S
            (NP
              (NP (JJ low)
                (NP (NN power) (JJ magnetic) (NN resonance))
                (NN imaging))
              (PRN (-LRB- -LRB-)
                (NP (NN MRI))
                (-RRB- -RRB-)))
            (VP (MD could)
              (VP (VB identify)
                (NP
                  (ADJP (RB mammographically) (JJ undetectable))
                  (NNS tumors))
                (PP (IN by)
                  (S
                    (VP (VBG applying)
                      (NP (PRP it))
                      (PP (TO to)
                        (NP (DT a) (JJ high) (NN risk) (NN population))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Tumors))
        (VP (VBN detected)
          (PP (IN by)
            (NP (DT this) (JJ new) (NN technology)))))
      (VP
        (VP (MD could)
          (VP (VB have)
            (NP (JJ unique)
              (NP
                (NP (NNS etiologies))
                (CC and/or)
                (NP (NNS presentations))))))
        (, ,)
        (CC and)
        (VP (MD may)
          (VP (VB represent)
            (NP
              (NP (DT an) (VBG increasing) (NN proportion))
              (PP (IN of)
                (NP (JJ clinical) (NN practice))))
            (SBAR (IN as)
              (S
                (NP (JJ new) (NN screening) (NNS methods))
                (VP (VBP are)
                  (VP
                    (VP (VBN validated))
                    (CC and)
                    (VP (VBN applied))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A)
          (ADJP (RB very) (JJ important))
          (NN aspect))
        (PP (IN of)
          (NP (DT this) (NN etiology))))
      (VP (VBZ is)
        (NP
          (NP (JJ genomic) (NN instability))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (VP (VBZ is)
                (VP (VBN associated)
                  (PP (IN with)
                    (NP
                      (NP (DT the) (NN loss))
                      (PP (IN of)
                        (NP
                          (NP (NN activity))
                          (PP (IN of)
                            (NP (DT the) (NN breast) (JJ cancer-predisposing) (NNS genes)
                              (NP
                                (NP (NN BRCA1))
                                (CC and)
                                (NP (NN BRCA2))))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (JJ sporadic) (NN breast) (NN cancer)))
      (, ,)
      (ADVP (RB however))
      (, ,)
      (NP (EX there))
      (VP (VBZ is)
        (NP
          (NP (NN evidence))
          (PP (IN for)
            (NP
              (NP
                (NP (DT the) (NN involvement))
                (PP (IN of)
                  (NP
                    (NP (DT a) (JJ different) (NN pathway))
                    (PP (IN of)
                      (NP (NN DNA) (NN repair))))))
              (, ,)
              (NP
                (NP (NN nucleotide) (NN excision) (NN repair))
                (PRN (-LRB- -LRB-)
                  (NP (NN NER))
                  (-RRB- -RRB-)))
              (, ,)
              (SBAR
                (WHNP (WDT which))
                (S
                  (VP (VBZ remediates)
                    (NP
                      (NP (NNS lesions))
                      (SBAR
                        (WHNP (WDT that))
                        (S
                          (VP (VBP cause)
                            (NP
                              (NP (DT a) (NN distortion))
                              (PP (IN of)
                                (NP (DT the) (NN DNA) (NN helix))))
                            (, ,)
                            (S
                              (VP (VBG including)
                                (NP (NN DNA) (NNS cross-links))))))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Case) (NN presentation))
      (: :)
      (S
        (NP (PRP We))
        (VP (VBP describe)
          (NP
            (NP (DT a) (NN breast) (NN cancer) (NN patient))
            (PP (IN with)
              (NP
                (NP (DT a)
                  (ADJP (RB mammographically) (JJ undetectable))
                  (NN stage) (NN I) (NN tumor))
                (VP (VBN identified)
                  (PP (IN in)
                    (NP (PRP$ our) (NN MRI) (NN screening) (NN study)))))))))
      (. .))))

(
  (S
    (S
      (NP (PRP She))
      (VP
        (VP (VBD was)
          (ADVP (RB originally))
          (VP (VBN considered)
            (S
              (VP (TO to)
                (VP (VB be)
                  (PP (IN at)
                    (NP
                      (NP (JJ high) (NN risk))
                      (PP (IN due) (TO to)
                        (NP
                          (NP (DT the) (JJ familial) (NN occurrence))
                          (PP (IN of)
                            (NP
                              (NP (NN breast))
                              (CC and)
                              (NP
                                (NP (JJ other) (NNS types))
                                (PP (IN of)
                                  (NP (NN cancer)))))))))))))))
        (, ,)
        (CC and)
        (PP (IN after)
          (NP (NN diagnosis)))
        (VP (VBD was)
          (VP (VBN confirmed)
            (PP (IN as)
              (NP
                (NP (DT a) (NN carrier))
                (PP (IN of)
                  (NP
                    (NP (DT a) (NN Q1200X) (NN mutation))
                    (PP (IN in)
                      (NP (DT the) (NN BRCA1) (NN gene)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (ADJP (FW In) (FW vitro))
          (NN analysis))
        (PP (IN of)
          (NP (PRP$ her) (JJ normal) (NN breast) (NN tissue))))
      (VP (VBD showed)
        (NP
          (NP (DT no) (NNS differences))
          (PP (IN in)
            (NP
              (NP (NN growth) (NN rate))
              (CC or)
              (NP (NN differentiation) (NN potential))))
          (PP (IN from)
            (NP (JJ disease-free) (NNS controls))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Analysis))
        (PP (IN of)
          (NP
            (NP (VBN cultured) (NN blood) (NN lymphocyte)
              (CC and)
              (NN breast) (NN epithelial) (NN cell) (NNS samples))
            (PP (IN with)
              (NP (DT the) (JJ unscheduled) (NN DNA) (NN synthesis) (-LRB- -LRB-) (NN UDS) (-RRB- -RRB-) (NN assay))))))
      (VP (VBD revealed)
        (NP
          (NP (DT no) (NN deficiency))
          (PP (IN in)
            (NP (NN NER))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Conclusion))
      (: :)
      (S
        (SBAR (IN As)
          (S
            (NP (JJ new) (NN breast) (NN cancer) (NN screening) (NNS methods))
            (VP (VBP become)
              (ADJP
                (ADJP (JJ available))
                (CC and)
                (ADJP (NN cost) (JJ effective))))))
        (, ,)
        (NP
          (NP (NNS patients))
          (PP (JJ such) (IN as)
            (NP (DT this) (NN one))))
        (MD will)
        (VP (VBP constitute)
          (NP
            (NP (DT an) (VBG increasing) (NN proportion))
            (PP (IN of)
              (NP (DT the) (JJ incident) (NN population))))
          (, ,)
          (SBAR (IN so)
            (S
              (NP (PRP it))
              (VP (VBZ is)
                (ADJP (JJ important))
                (S
                  (VP (TO to)
                    (VP (VB determine)
                      (SBAR (IN whether)
                        (S
                          (NP (PRP they))
                          (VP (VBP differ)
                            (PP (IN from)
                              (NP (JJ current) (NNS patients)))
                            (PP (IN in)
                              (NP (DT any)
                                (ADJP (RB clinically) (JJ important))
                                (NNS ways))))))))))))))
      (. .))))

(
  (S
    (PP (IN Despite)
      (NP
        (NP (PRP$ her) (NN status))
        (PP (IN as)
          (NP
            (NP (DT a) (NN BRCA1) (NN mutation) (NN carrier))
            (, ,)
            (CC and)
            (NP (PRP$ her)
              (ADJP (RB mammographically) (JJ dense))
              (NN breast) (NN tissue))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD did) (RB not)
      (VP (VB find)
        (NP
          (NP
            (NP (VBN increased) (NN cell) (NN proliferation))
            (CC or)
            (NP (JJ deficient) (NN differentiation) (NN potential)))
          (PP (IN in)
            (NP
              (NP (NN breast) (JJ epithelial) (NNS cells))
              (PP (IN from)
                (NP
                  (NP (DT this) (NN patient))
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (VP (MD might)
                        (VP (VB have)
                          (VP (VBN contributed)
                            (PP (TO to)
                              (NP (PRP$ her) (NN cancer) (NN susceptibility)))))))))))))))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP (NN NER) (NN deficiency))
        (VP (VBZ has)
          (VP (VBN been)
            (VP (VBN demonstrated)
              (ADVP (RB repeatedly))
              (PP (IN in)
                (NP
                  (NP (NN blood) (NNS samples))
                  (PP (IN from)
                    (NP (JJ sporadic) (NN breast) (NN cancer) (NNS patients))))))))))
    (, ,)
    (NP
      (NP (NN analysis))
      (PP (IN of)
        (NP
          (NP (NN blood) (VBN cultured) (NNS lymphocytes))
          (CC and)
          (NP (NN breast) (JJ epithelial) (NNS cells))))
      (PP (IN for)
        (NP (DT this) (NN patient))))
    (VP (VBZ proves)
      (ADVP (RB definitively))
      (SBAR (IN that)
        (S
          (NP
            (NP (NN heterozygosity))
            (PP (IN for)
              (NP
                (NP (NN inactivation))
                (PP (IN of)
                  (NP (NN BRCA1))))))
          (VP (VBZ does) (RB not)
            (ADVP (RB intrinsically))
            (VP (VB confer)
              (NP
                (NP (DT this) (NN type))
                (PP (IN of)
                  (NP (JJ genetic) (NN instability)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (NN mechanism))
              (PP (IN of)
                (NP
                  (NP (JJ genomic) (NN instability))
                  (VP (VBG driving)
                    (NP (DT the) (NN carcinogenic) (NN process))))))
            (VP (MD may)
              (VP (VB be)
                (ADJP (RB fundamentally) (JJ different)
                  (PP (IN in)
                    (NP (JJ hereditary)
                      (CC and)
                      (JJ sporadic) (NN breast) (NN cancer))))
                (, ,)
                (S
                  (VP (VBG resulting)
                    (PP (IN in)
                      (NP
                        (NP (JJ different) (JJ genotoxic) (NNS susceptibilities))
                        (, ,)
                        (NP (NN oncogene) (NNS mutations))
                        (, ,)
                        (CC and)
                        (NP (DT a) (JJ different) (JJ molecular) (NN pathogenesis))))))))))))
    (. .)))

(
  (S
    (NP (NN Background))))

(
  (S
    (S
      (NP
        (NP (DT A) (NN reduction))
        (PP (IN in)
          (NP (NN breast) (NN cancer) (NN mortality))))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN observed)
            (PP (IN in)
              (NP
                (NP (JJ recent) (NNS years))
                (SBAR
                  (WHNP (WDT that))
                  (S
                    (VP (VBZ has)
                      (VP (VBN been)
                        (ADVP (RB partially))
                        (VP (VBN attributed)
                          (PP (TO to)
                            (NP
                              (NP (DT the) (JJ widespread) (NN adoption))
                              (PP (IN of)
                                (NP (NN screening) (NN mammography) (CD -LSB-1) (-RRB- -RSB-))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Traditional) (NN screening) (NN mammography))
      (, ,)
      (ADVP (RB however))
      (, ,)
      (VP (VBZ fails)
        (S
          (VP (TO to)
            (VP (VB detect)
              (NP
                (NP (CD 15) (NN %))
                (PP (IN of)
                  (NP
                    (NP (JJ incident) (NNS cancers))
                    (PRN (NN -LSB-2) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ New) (, ,) (JJ complementary) (NN imaging) (NNS techniques))
      (VP (VBP are)
        (ADVP (RB therefore))
        (PP (IN under)
          (NP
            (NP (NN development))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (MD may)
                  (VP (VB increase)
                    (NP
                      (NP (DT the) (NN accuracy))
                      (PP (IN of)
                        (NP (JJ primary) (NN screening))))))))))))
    (. .)))

(
  (S
    (NP (PRP We))
    (VP (VBD performed)
      (NP
        (NP (DT a) (JJ small) (NN study))
        (S
          (VP
            (VP (TO to)
              (VP (VB validate)
                (NP
                  (NP (DT the) (NN use))
                  (PP (IN of)
                    (NP (JJ low) (NN power)
                      (NP
                        (NP (JJ magnetic) (NN resonance) (VBG imaging))
                        (PRN (-LRB- -LRB-)
                          (NP (NN MRI))
                          (-RRB- -RRB-)))))
                  (S
                    (VP (TO to)
                      (ADVP (RB prospectively))
                      (VP (VB detect)
                        (NP
                          (NP (NN breast) (NNS alterations))
                          (CC and)
                          (NP (NN malignancy)))))))))
            (CC and)
            (VP (TO to)
              (VP (VB determine)
                (NP
                  (NP (DT the) (NN feasibility))
                  (PP (IN of)
                    (S
                      (VP (VBG applying)
                        (NP (DT this) (NN technique))
                        (PP (TO to)
                          (NP
                            (NP (DT a) (JJ high-risk) (NN population))
                            (PRN (NN -LSB-3) (-RRB- -RSB-))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP present)
        (ADVP (RB here))
        (NP
          (NP (DT a) (NN subject))
          (PP (IN from)
            (NP (DT that) (NN study)))
          (SBAR
            (WHNP (WP$ whose) (JJ early) (NN stage) (NN tumor))
            (S
              (VP (VBD was) (RB not)
                (ADJP (JJ detectable)
                  (PP (IN by)
                    (NP (NN mammography))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN patient))
      (VP (VBD was)
        (VP (VBN enrolled)
          (PP (IN in)
            (NP
              (NP (DT the) (JJ screening) (NN study))
              (ADJP (JJ due)
                (PP (TO to)
                  (NP
                    (NP (PRP$ her) (NN family) (NN history))
                    (PP (IN of)
                      (NP
                        (NP (NN breast))
                        (CC and)
                        (NP (JJ other) (NNS neoplasias))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (NN tumor) (NN diagnosis)))
      (, ,)
      (NP (PRP she))
      (VP (VBD was)
        (VP (VBN determined)
          (S
            (VP (TO to)
              (VP (VB be)
                (ADJP (JJ heterozygous)
                  (PP (IN for)
                    (NP
                      (NP (DT a) (JJ putative) (VBG inactivating) (NN mutation))
                      (PP (IN in)
                        (NP (DT the) (NN BRCA1) (NN gene))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (PRP she))
      (VP (VBD had)
        (NP
          (NP (JJ dense) (NN breast) (NN tissue))
          (, ,)
          (NP
            (NP (DT an) (NN impediment))
            (PP (TO to)
              (NP (NN mammography)))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (VBZ is)
                  (PP (IN in)
                    (NP (PRP itself)))
                  (NP
                    (NP (DT a) (NN risk) (NN factor))
                    (PP (IN for)
                      (NP (NN breast) (NN cancer) (CD -LSB-4))))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Breast) (NN development))
        (CC and)
        (NP (JJ lactational) (NN differentiation)))
      (ADVP (RB also))
      (VP (VBP appear)
        (S
          (VP (TO to)
            (ADVP (RB individually))
            (VP (VB modify)
              (NP (NN breast) (NN cancer) (NN risk)))))
        (, ,)
        (PP (IN with)
          (NP
            (NP (JJ early) (NN term) (NN pregnancy))
            (VP (VBG conferring)
              (NP (DT a) (JJ persistent) (JJ protective) (NN effect) (CD -LSB-5) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Exposure))
        (PP (TO to)
          (NP (VBG ionizing) (NN radiation))))
      (, ,)
      (PP (IN while)
        (NP
          (NP (DT a) (JJ lifetime) (NN risk) (NN factor))
          (PP (IN for)
            (NP (NN breast) (NN cancer)))))
      (, ,)
      (VP (VBZ appears)
        (S
          (VP (TO to)
            (VP (VB be)
              (ADJP (RBR more) (JJ dangerous)))
            (SBAR
              (WHADVP (WRB when))
              (S
                (NP (PRP it))
                (VP (VBZ occurs)
                  (PP (IN during)
                    (NP
                      (NP (JJ alveolar) (NN differentiation))
                      (PP (IN of)
                        (NP (DT the) (NN breast)))))
                  (PP (IN at)
                    (NP (NN adolescence) (CD -LSB-6))))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (VP (VBG Using)
        (NP (DT a) (JJ novel) (NN tissue) (NN engineering) (NN system) (CD -LSB-7)))
      (-RRB- -RSB-))
    (, ,)
    (NP (PRP we))
    (ADVP (RB therefore))
    (VP (VBD examined)
      (NP
        (NP (DT the)
          (NP
            (NP (NN growth))
            (CC and)
            (NP (NN differentiation))))
        (PP (IN of)
          (NP
            (NP (JJ normal) (NN breast) (JJ epithelial) (NNS samples))
            (PP (IN from)
              (NP (DT this) (NN patient))))))
      (PP (IN via)
        (NP (JJ live-cell) (NN imaging))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN BRCA1)
        (NP (JJ hereditary) (NN breast) (NN cancer))
        (NN gene))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN shown)
            (S
              (VP (TO to)
                (VP (VB be)
                  (VP (VBN involved)
                    (PP (IN in)
                      (NP (NN DNA) (JJ double) (NN strand) (NN break) (NN repair) (CD -LSB-8,9) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (NN DNA) (NN repair))
          (NNS defects))
        (VP (VBP have)
          (ADVP (RB also))
          (VP (VBN been)
            (VP (VBN identified)
              (PP (IN in)
                (NP
                  (NP (DT the) (JJ peripheral) (NN blood) (NNS cells))
                  (PP (IN of)
                    (NP (JJ sporadic) (NN breast) (NN cancer) (NNS patients) (CD -LSB-10-13) (-RRB- -RSB-)))))))))
      (, ,)
      (CC but)
      (S (, ,)
        (PP (IN in)
          (NP (DT this) (NN case)))
        (, ,)
        (NP (PRP it))
        (VP (VBZ seems)
          (S
            (VP (TO to)
              (VP (VB involve)
                (NP
                  (NP (DT a) (JJ different) (NN pathway))
                  (PP (IN of)
                    (NP
                      (NP (NN DNA) (NN repair))
                      (, ,)
                      (NP (NN nucleotide) (NN excision) (NN repair))
                      (PRN (-LRB- -LRB-)
                        (NP (NN NER))
                        (-RRB- -RRB-))
                      (NP (NN -LSB-14-16))
                      (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (VP (VBN extended)
          (NP
            (NP
              (NP (DT this) (NN observation))
              (PP (IN of)
                (NP (NN NER) (NN deficiency)))
              (PP (TO to)
                (NP (DT the) (NN tumor) (PRP itself))))
            (, ,)
            (CONJP (RB as) (RB well) (IN as))
            (NP (DT the) (JJ adjoining) (JJ non-diseased) (JJ normal) (NN breast) (NN tissue) (CD -LSB-17))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP (NN NER))
      (VP (VBZ is)
        (NP
          (NP (DT a) (JJ complex) (NN pathway))
          (PP (IN of)
            (NP (NN DNA) (NN repair) (CD -LSB-18) (-RRB- -RSB-)))
          (VP
            (ADVP (RB normally))
            (VBN associated)
            (PP (IN with)
              (NP
                (NP (NN removal))
                (PP (IN of)
                  (NP
                    (NP
                      (NP (JJ pyrimidine-pyrimidine) (JJ intrastrand) (NNS crosslinks))
                      (PRN (-LRB- -LRB-)
                        (NP (NN “dimers) (NN ''))
                        (-RRB- -RRB-)))
                    (VP (VBN caused)
                      (PP (IN by)
                        (NP
                          (NP (NN exposure))
                          (PP (TO to)
                            (NP (NN UV) (NN light))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN NER) (NN deficiency))
      (VP (VBZ is)
        (NP
          (NP (DT the) (NN basis))
          (PP (IN of)
            (NP
              (NP
                (NP (JJ hereditary) (NN xeroderma) (NN pigmentosum))
                (PRN (-LRB- -LRB-)
                  (NP (NN XP) (-RRB- -RRB-) (CD -LSB-19))
                  (-RRB- -RSB-)))
              (, ,)
              (NP
                (NP (DT a) (NN disease))
                (PP (IN with)
                  (NP
                    (NP (DT a)
                      (ADJP (RB 1200-fold))
                      (NN increase))
                    (PP (IN in)
                      (NP
                        (NP (NN incidence))
                        (PP (IN of)
                          (NP (NN skin) (NN cancer) (CD -LSB-20)))))))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN signal))
        (PP (IN for)
          (NP
            (NP (NN activation))
            (PP (IN of)
              (NP (DT the) (NN NER) (NN pathway))))))
      (VP (VBZ is)
        (ADVP (RB actually))
        (ADJP (RB very) (JJ general))))
    (: ;)
    (S
      (NP (DT any) (NN lesion))
      (VP (VBG causing)
        (NP
          (NP (DT a) (NN distortion))
          (PP (IN in)
            (NP (DT the) (NN DNA) (NN helix)))
          (, ,)
          (PP (VBG including)
            (NP
              (NP (NNS crosslinks))
              (VP (VBN caused)
                (PP (IN by)
                  (NP
                    (NP
                      (NP (JJ oxidative) (NNS radicals))
                      (, ,)
                      (NP
                        (NP (JJ certain) (NNS types))
                        (PP (IN of)
                          (NP
                            (NP (NNS mismatches))
                            (PRN (-LRB- -LRB-)
                              (NP
                                (NP (NN purine-purine))
                                (CC or)
                                (NP (NN pyrimidine-pyrimidine)))
                              (-RRB- -RRB-)))))
                      (CC and)
                      (NP
                        (ADJP (RB so) (VBN called))
                        (NN “bulky) (NN '') (NNS adducts)))
                    (VP (VBN caused)
                      (PP (IN by)
                        (NP
                          (NP (NN phase) (NN I) (NN metabolism))
                          (PP (IN of)
                            (NP (NN polyaromatic) (NNS hydrocarbons) (CD -LSB-21) (-RRB- -RSB-))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ has)
        (ADVP (RB recently))
        (VP (VBN been)
          (VP (VBN shown)
            (SBAR (IN that)
              (S
                (NP (NN BRCA1) (NN expression))
                (VP (MD can)
                  (VP (VB enhance)
                    (NP (NN NER) (NN activity))
                    (, ,)
                    (SBAR (IN although)
                      (S
                        (NP (DT this) (NN analysis))
                        (VP (VBD was) (RB not)
                          (VP (VBN performed)
                            (PP (IN in)
                              (NP (NN breast) (NNS cells)))
                            (NP (CD -LSB-22,23))
                            (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB therefore))
      (VP (VBN applied)
        (NP
          (NP (DT the) (JJ functional) (JJ unscheduled) (NN DNA) (NN synthesis) (-LRB- -LRB-) (NN UDS) (-RRB- -RRB-) (NN assay))
          (PP (IN for)
            (NP (NN NER) (NN capacity))))
        (PP (TO to)
          (NP
            (NP (JJ multiple) (NNS samples))
            (PP (IN of)
              (NP
                (NP (JJ normal) (NN tissue))
                (PP (IN from)
                  (NP (DT this) (NN patient)))))))
        (, ,)
        (S
          (VP (TO to)
            (VP (VB determine)
              (SBAR (IN whether)
                (S
                  (NP
                    (NP (NN haploinsufficiency))
                    (PP (IN for)
                      (NP (NN BRCA1))))
                  (VP (VBD was)
                    (NP
                      (NP (DT a) (NN mechanism))
                      (PP (IN of)
                        (NP (NN NER) (NN deficiency))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (VP (VBN developed)
          (NP
            (NP (DT a) (NN method))
            (S
              (VP (TO to)
                (ADVP (RB reliably))
                (VP (NN culture)
                  (NP
                    (NP
                      (NP (JJ non-diseased) (NN breast) (NN tissue))
                      (PRN (-LRB- -LRB-)
                        (PP (IN with)
                          (NP
                            (NP (DT a) (NN success) (NN rate))
                            (PP (IN of)
                              (NP (CD 100) (NN %)))))
                        (-RRB- -RRB-)))
                    (CC and)
                    (NP
                      (NP (NN breast) (NNS tumors))
                      (PRN (-LRB- -LRB-)
                        (PP (IN with)
                          (NP
                            (NP (DT a) (NN success) (NN rate))
                            (PP (IN of)
                              (NP (CD 85) (NN %)))))
                        (-RRB- -RRB-)
                        (NP (CD -LSB-7,17))
                        (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (NP (NN Case) (NN presentation))))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP describe)
        (NP
          (NP (DT a) (NN breast) (NN cancer) (NN patient))
          (SBAR
            (WHNP (WP$ whose) (NN tumor))
            (S
              (VP (VBD was)
                (VP (VBN detected)
                  (PP (IN by)
                    (NP (NN MRI))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP She))
      (VP (VBD was)
        (VP (VBN enrolled)
          (PP (IN into)
            (NP
              (NP (DT a) (NN pilot) (NN screening) (NN study))
              (PP (IN of)
                (NP
                  (NP (JJ low) (NN power) (NN MRI))
                  (PP (IN due) (TO to)
                    (NP (PRP$ her) (JJ familial) (NN risk))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (PRP She))
        (VP (VBD had)
          (NP
            (ADJP (RB mammographically) (JJ dense))
            (NNS breasts))))
      (CC and)
      (S
        (NP (PRP$ her) (NN tumor))
        (VP (VBD was)
          (ADJP (JJ undetectable)
            (ADVP (RB mammographically))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN patient))
      (VP (VBD was)
        (NP
          (NP (DT a)
            (ADJP (CD 35.7) (NN year) (JJ old))
            (NN woman))
          (SBAR
            (WHNP (WP who))
            (S
              (VP (VBD presented)
                (PP (IN with)
                  (NP
                    (NP
                      (NP (DT a)
                        (ADJP (RB very) (JJ strong))
                        (NN family) (NN history))
                      (PP (IN of)
                        (NP (NN breast) (NN cancer)))
                      (SBAR (IN as)
                        (S
                          (VP (VBN depicted)
                            (PP (IN in)
                              (NP (NN Figure) (CD 1))))))
                      (, ,))
                    (CC and)
                    (NP (JJ negative)
                      (ADJP
                        (ADJP (JJ physical))
                        (CC and)
                        (ADJP (JJ mammographic)))
                      (NN examination))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP She))
      (VP (VBD had)
        (NP
          (NP
            (NP
              (ADJP (RB extremely) (JJ dense))
              (NN breast) (NN tissue) (NN bilaterally))
            (PP (IN by)
              (NP (NN mammography))))
          (CONJP (RB as) (RB well) (IN as))
          (NP (JJ fibrocystic) (NN breast) (NN tissue)))
        (PP (IN by)
          (NP (JJ physical) (NN examination)))))
    (. .)))

(
  (S
    (S
      (NP (PRP She))
      (VP (VBD had)
        (NP
          (NP (DT no) (JJ previous) (JJ personal) (NN history))
          (PP (IN of)
            (NP
              (NP (NN breast) (NN biopsy))
              (CC or)
              (NP (JJ abnormal) (NNS mammograms)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (DT The)
            (ADJP (CD 5) (NN year))
            (NN breast) (NN cancer) (NN risk))
          (PP (IN for)
            (NP
              (NP (DT this) (NN patient))
              (SBAR (IN as)
                (S
                  (VP (VBN calculated)
                    (PP (IN by)
                      (NP (DT the) (NN BRCAPRO) (NN model)))))))))
        (VP (VBD was)
          (NP (CD 5.7) (NN %))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (PRP$ her) (NN probability))
          (PP (IN of)
            (S
              (VP (VBG being)
                (NP (DT a)
                  (NP
                    (NP (NN BRCA1))
                    (CC or)
                    (NP (NN BRCA2)))
                  (NN carrier))))))
        (VP (VBD was)
          (NP (CD 0.47)))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN Gail) (NN model) (NN risk) (NN assessment))
      (VP (VBD was)
        (VP (VBN calculated)
          (S
            (VP (VBG using)
              (NP
                (NP (DT the) (VBG following) (NN information))
                (: :)
                (NP (NN Race-Caucasian))
                (: ;)
                (NP (NN Age-35))
                (: ;)
                (NP
                  (NP (NN Age))
                  (PP (IN at)
                    (NP (JJ first) (NN menses-12))))
                (: ;)
                (NP
                  (NP (NN Age))
                  (PP (IN at)
                    (NP (JJ first) (JJ live) (NN birth-nulliparous))))
                (: ;)
                (NP
                  (NP (NN Number))
                  (PP (IN of)
                    (NP
                      (NP (JJ first-degree) (NNS relatives))
                      (PP (IN with)
                        (NP (NN breast) (NN cancer-2))))))
                (: ;)
                (NP
                  (NP (NN Number))
                  (PP (IN of)
                    (NP (JJ previous) (NN breast) (NN biopsies-0))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT The) (VBN calculated)
          (ADJP (CD 5) (NN year))
          (NN Gail) (NN risk))
        (VP (VBD was)
          (NP (CD 1.0) (NN %))))
      (CC and)
      (S
        (NP (PRP$ her) (NN lifetime) (NN risk))
        (VP (VBD was)
          (NP (CD 31.3) (NN %)))))
    (. .)))

(
  (S
    (S
      (PP (VBG Following)
        (NP (JJ genetic) (NN counseling)))
      (, ,)
      (NP (DT the) (NN patient))
      (VP (VBD elected)
        (S
          (VP (TO to)
            (VP (VB undergo)
              (NP
                (NP (NN DNA) (NN sequencing))
                (PP (IN of)
                  (NP
                    (NP (DT the)
                      (NP
                        (NP (NN BRCA1))
                        (CC and)
                        (NP (NN BRCA2)))
                      (NNS genes))
                    (, ,)
                    (SBAR
                      (WHNP (WDT which))
                      (S
                        (VP (VBD revealed)
                          (NP
                            (NP (DT a) (JJ Q1200X) (NN truncation) (NN mutation))
                            (PP (IN in)
                              (NP
                                (NP (CD one))
                                (PP (IN of)
                                  (NP (PRP$ her) (NN BRCA1) (NNS alleles)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN C) (TO to) (NN T) (NN mutation))
        (PP (IN at)
          (NP (NN codon) (CD 1200)))
        (PP (IN in)
          (NP (NN exon) (CD 11))))
      (VP (VBZ results)
        (PP (IN in)
          (NP
            (NP (DT the) (NN change))
            (PP (IN of)
              (NP
                (NP (DT the) (NN amino) (NN acid) (NN glutamine))
                (PP (TO to)
                  (NP (DT a) (NN stop) (NN codon)))
                (PP (IN with)
                  (NP
                    (NP (VBG resulting) (NN protein) (NN truncation))
                    (CC and)
                    (NP
                      (NP (NN loss))
                      (PP (IN of)
                        (NP (NN function))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Exon) (CD 11))
      (VP
        (VP (VBZ is)
          (NP
            (NP (DT the) (JJS largest) (NN exon))
            (PP (IN in)
              (NP (NN BRCA1)))))
        (CC and)
        (VP (VBZ has)
          (NP
            (NP (DT the) (JJS highest) (NN frequency))
            (PP (IN of)
              (NP (VBN reported) (NNS mutations)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN Q1200X) (NN mutation))
      (VP (VBZ has)
        (VP (VBN been)
          (ADVP (RB independently))
          (VP (VBN observed)
            (NP (JJ several) (NNS times) (CD -LSB-24) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ bilateral) (NN screening) (NN mammogram))
      (VP (VBD was)
        (VP (VBN compared)
          (PP (TO to)
            (NP
              (NP (JJ previous) (NNS films))
              (PP (IN from)
                (NP (DT another) (NN hospital))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN breast) (NN tissue))
      (VP (VBD was)
        (VP (VBN described)
          (PP (IN as)
            (ADJP (RB heterogeneously) (JJ dense)))
          (, ,)
          (S
            (ADVP (RB thus))
            (VP (VBG lowering)
              (NP (DT the) (NN sensitivity)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (EX There))
        (VP (VBD were)
          (NP
            (NP (DT no) (NNS masses))
            (, ,)
            (NP
              (NP (JJ significant) (NNS calcifications))
              (CC or)
              (NP (JJ other) (NNS findings))))))
      (CC and)
      (S
        (NP (DT the) (NN mammogram))
        (VP (VBD was)
          (VP (VBN interpreted)
            (PP (IN as)
              (NP (JJ negative) (NN bilaterally)))))))
    (. .)))

(
  (S
    (S
      (NP (DT A) (JJ one-year) (NN follow-up))
      (VP (VBD was)
        (VP (VBN recommended))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN patient))
      (VP (VBD was)
        (ADVP (RB then))
        (VP (NN MRI) (VBN scanned)
          (PP (IN as)
            (NP
              (ADJP (RB previously) (VBN described))
              (NN -LSB-3) (-RRB- -RSB-)))
          (, ,)
          (PP (IN with)
            (NP
              (NP
                (ADJP
                  (ADJP (JJ pre-))
                  (CC and)
                  (ADJP (JJ post-gadolinium)))
                (NN enhancement) (NNS images))
              (VP (VBG evaluating)
                (NP (DT both) (NNS breasts))
                (PP
                  (ADVP (RB simultaneously))
                  (IN in)
                  (NP (DT the) (JJ axial) (NN plane)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ upper-outer) (JJ left) (NN breast)))
      (NP (EX there))
      (VP (VBD was)
        (NP (DT a)
          (ADJP
            (ADJP (JJ small)
              (PRN (-LRB- -LRB-)
                (NP
                  (QP (RB approximately) (CD 1))
                  (NN cm))
                (-RRB- -RRB-)))
            (, ,)
            (ADJP (JJ round))
            (, ,)
            (ADJP (JJ well-demarcated)))
          (NN enhancing) (NN lesion))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN lesion))
      (VP (VBD was)
        (VP (VBN seen)
          (PP (IN on)
            (NP (CC both)
              (NP
                (NP (DT the) (JJ initial) (NN delay))
                (PP (IN after)
                  (NP (NN contrast) (NN injection))))
              (CC and)
              (NP (DT the) (VBN delayed)
                (ADJP
                  (NP (NN contrast))
                  (VBN enhanced))
                (NN subtraction) (NNS images)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN lesion))
      (VP (VBD appeared)
        (S
          (VP (TO to)
            (VP (VB accumulate)
              (NP
                (NP (NN contrast))
                (PP (TO to)
                  (NP (DT a) (JJR greater) (NN extent))))
              (PP (IN on)
                (NP (DT the) (VBN delayed) (NN subtraction) (NNS images)))
              (PP (IN with)
                (NP
                  (NP (DT an) (JJ additional) (NN lesion))
                  (ADJP (JJ adjacent)
                    (PP (TO to)
                      (NP (DT the) (JJ first)))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP
        (NP (DT the) (JJ medial) (NN aspect))
        (PP (IN of)
          (NP (DT the) (JJ mid) (JJ right) (NN breast)))))
    (, ,)
    (NP (EX there))
    (VP (VBD were)
      (NP
        (NP (JJ several) (JJ small) (NN punctate) (NNS areas))
        (PP (IN of)
          (NP (NN enhancement)))
        (PP (IN on)
          (NP (CC both)
            (NP (DT the) (JJ immediate))
            (CC and)
            (NP (VBN delayed) (NN subtraction) (NNS views))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Also))
      (PP (IN in)
        (NP
          (NP (DT the) (JJ right) (NN breast))
          (PP
            (ADVP (RB just))
            (IN above)
            (NP
              (NP (DT the) (NN nipple) (NN level))
              (ADJP
                (ADJP (JJ medial))
                (CC and)
                (ADJP (JJ close)
                  (PP (TO to)
                    (NP (DT the) (NN chest) (NN wall)))))))))
      (NP (DT an) (JJ additional) (NN enhancing) (NN lesion))
      (VP (VBD was)
        (VP (VBN seen))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN lesion))
      (VP
        (VP (VBD was)
          (ADJP
            (ADJP
              (QP (RB approximately) (CD 1.5))
              (NN cm))
            (, ,)
            (ADJP (JJ round))
            (, ,)
            (ADJP (JJ well-demarcated))))
        (CC and)
        (VP (VBD continued)
          (S
            (VP (TO to)
              (VP (VB accumulate)
                (NP
                  (NP (NN contrast))
                  (PP (IN on)
                    (NP (DT the) (VBN delayed) (NN subtraction) (NNS images))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN lesion))
      (VP (VBD appeared)
        (S
          (VP (TO to)
            (VP (VB have)
              (NP (DT a) (JJ small) (JJ non-enhancing) (NN septation)))))))
    (. .)))

(
  (S
    (S
      (PP (IN Under)
        (NP (NN ultrasound)))
      (, ,)
      (NP
        (NP (DT the) (NN lesion))
        (PP (IN of)
          (NP (NN concern)))
        (PP (IN in)
          (NP (DT the) (JJ left) (NN breast))))
      (VP (VBD was)
        (VP
          (VP (VBN identified))
          (CC and)
          (VP (VBN biopsied))))
      (, ,)
      (CONJP (RB as) (RB well) (IN as))
      (NP
        (NP (CD one) (NN lesion))
        (PP (IN in)
          (NP
            (NP (DT the) (JJ right) (NN breast))
            (PRN (-LRB- -LRB-)
              (NP (NN Figure) (CD 2))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN core) (NN biopsy))
        (PP (IN of)
          (NP (DT the) (JJ left) (NN breast))))
      (VP (VBD revealed)
        (NP
          (NP
            (NP (JJ infiltrating) (JJ ductal) (NN carcinoma))
            (PP (IN in)
              (NP
                (NP (CD 2))
                (PP (IN of)
                  (NP (CD 5) (NN core) (NNS fragments))))))
          (: ;)
          (NP (JJ high) (JJ nuclear) (NN grade)))
        (, ,)
        (PP (IN with)
          (NP
            (NP (DT no) (JJ lymphatic) (NN invasion))
            (VP (VBN seen))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN core) (NN biopsy))
        (PP (IN of)
          (NP (DT the) (JJ right) (NN breast))))
      (VP (VBD demonstrated)
        (NP (JJ benign) (NN pathology))
        (, ,)
        (ADVP (RB specifically))
        (, ,)
        (NP (NN fibrosis))
        (PP (IN with)
          (NP (JJ focal) (JJ ductal) (NN epithelial) (NN hyperplasia)))))
    (. .)))

(
  (S
    (PP (IN Although)
      (NP
        (NP (DT a) (JJ surgical) (NN candidate))
        (PP (IN for)
          (NP
            (NP (NN lumpectomy))
            (CC and)
            (NP (NN radiation))))))
    (, ,)
    (NP (DT the) (NN patient))
    (VP (VBP chose)
      (S
        (VP (TO to)
          (VP (VB undergo)
            (NP
              (NP (JJ left) (JJ modified) (NN radical) (NN mastectomy))
              (PP (IN with)
                (NP
                  (NP (JJ left) (NN axillary) (NN lymph) (NN node) (NN dissection))
                  (CC and)
                  (NP (JJ contralateral) (JJ prophylactic) (JJ total) (NN mastectomy)))))
            (PP (IN because) (IN of)
              (NP (PRP$ her) (JJ genetic) (NN risk) (NN status)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN pathology))
        (PP (IN in)
          (NP (DT the) (JJ left) (NN breast))))
      (VP (VBD was)
        (ADJP (JJ consistent)
          (PP (IN with)
            (NP
              (NP (DT the)
                (NP (NN imaging))
                (CC and)
                (NP (NN core) (NN biopsy)))
              (PP (IN in)
                (NP
                  (NP (NN size))
                  (CC and)
                  (NP (NN description)))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN Tumor) (NN size))
        (VP (VBD was)
          (ADJP (CD 8) (NN mm))
          (PP (IN in)
            (NP
              (NP (JJS greatest) (NN dimension))
              (, ,)
              (NP
                (NP (JJ nuclear) (NN grade) (CD III))
                (, ,)
                (NP (NN ER/PR))
                (CC and)
                (NP (NN Her2/neu) (JJ negative)))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (JJ nodal) (NN status))
          (PRN (-LRB- -LRB-)
            (NP (NN 0/4))
            (-RRB- -RRB-)))
        (VP (VBD was)
          (ADJP
            (ADJP (JJ negative))
            (PRN (-LRB- -LRB-)
              (NP (NN stage) (CD TIaN0M0))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN patient))
      (VP
        (VP (VBD underwent)
          (NP
            (NP (CD 4) (NNS cycles))
            (PP (IN of)
              (NP (NN chemotherapy)))))
        (CC and)
        (VP (VBZ has)
          (VP (VBN been)
            (ADJP (RB reportedly) (JJ healthy))
            (ADVP (IN since))))))
    (. .)))

(
  (S
    (S
      (PP (IN Because)
        (PP (IN of)
          (NP (DT the) (JJ positive) (NN BRCA1) (NN mutation) (NNS results))))
      (, ,)
      (NP (PRP she))
      (ADVP (RB subsequently))
      (VP (VBD underwent)
        (NP (JJ prophylactic) (JJ bilateral) (NN salpingo-oophorectomy))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NN number))
        (PP (IN of)
          (NP (NN life) (NN history) (NNS factors))))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN associated)
            (PP (IN with)
              (NP
                (NP (NN breast) (NN cancer) (NN incidence))
                (SBAR
                  (WHNP (WDT that))
                  (S
                    (VP (VBP are)
                      (ADVP (RB widely))
                      (VP (VBN interpreted)
                        (PP (IN as)
                          (S
                            (VP (VBG representing)
                              (NP
                                (NP (JJ lifetime) (NN exposure))
                                (PP (IN of)
                                  (NP (DT the) (NN breast) (NN tissue)))
                                (PP (TO to)
                                  (NP (JJ estrogen-induced) (NN mitogenesis) (CD -LSB-25)))))
                            (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT An) (JJ alternative) (NN interpretation))
        (, ,)
        (VP (VBN based)
          (PP (IN on)
            (NP (JJ epithelial) (NN cell) (NN differentiation))))
        (, ,))
      (VP (VBZ suggests)
        (SBAR (IN that)
          (S
            (NP
              (NP (JJ lactational) (NN differentiation))
              (, ,)
              (SBAR (JJ such) (IN as)
                (S
                  (VP (VBZ occurs)
                    (PP (IN during)
                      (NP (NN term) (NN pregnancy))))))
              (, ,))
            (VP (VBZ confers)
              (NP
                (NP (NN resistance))
                (PP (TO to)
                  (NP (NN carcinogenesis) (CD -LSB-26,27)))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (VP (VBN developed)
          (NP
            (NP (DT a) (JJ novel) (JJ human) (JJ mammary) (NN epithelial) (-LRB- -LRB-) (NN HME) (-RRB- -RRB-) (NN tissue) (NN engineering) (NN system) (NN wherein))
            (S
              (NP
                (NP (JJ many) (NNS aspects))
                (PP (IN of)
                  (NP (JJ organotypic) (NN differentiation))))
              (VP (VBP are)
                (VP (VBN reiterated)
                  (NP
                    (ADJP (FW in) (FW vitro))
                    (NN -LSB-28))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT this) (NN system)))
    (, ,)
    (NP (NN breast) (NN epithelial) (NNS cells))
    (ADVP (RB initially))
    (VP (VBP retain)
      (NP (JJ cell-to-cell) (NN contact))
      (SBAR (IN while)
        (S
          (NP (PRP they))
          (VP
            (VP (VBP proliferate))
            (, ,)
            (VP
              (ADVP (RB then))
              (VBP undergo)
              (NP (DT an) (JJ architectural) (NN reorganization)))
            (, ,)
            (ADVP (RB first))
            (S
              (VP (TO to)
                (VP (VB form)
                  (NP
                    (NP (JJ three-dimensional) (NNS mammospheres))
                    (, ,)
                    (CC and)
                    (NP
                      (NP (JJ later) (JJ vast) (NNS networks))
                      (PP (IN of)
                        (NP (NN branching) (JJ ductal)
                          (CC and)
                          (JJ lobular) (NNS structures))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Tumor))
        (CC and)
        (NP (DT some) (JJ pre-neoplastic) (NNS samples)))
      (VP (VBP fail)
        (S
          (VP (TO to)
            (VP (VB form)
              (NP (JJ such) (NN architecture)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Normal) (NN tissue))
        (PP (IN from)
          (NP
            (NP (DT this) (NN patient))
            (, ,)
            (SBAR
              (WHNP (WP who))
              (S
                (VP
                  (VP (VBZ is)
                    (NP (PDT both) (DT a) (NN BRCA1) (NN mutation) (NN carrier)))
                  (CC and)
                  (VP (VBZ has)
                    (NP (JJ dense) (NNS breasts))))))
            (, ,))))
      (VP (VBD was)
        (VP (VBN evaluated)
          (S
            (VP (TO to)
              (VP (VB determine)
                (SBAR (IN whether)
                  (S
                    (NP
                      (NP (DT either))
                      (PP (IN of)
                        (NP (DT these) (NNS factors))))
                    (VP (VBD affected)
                      (NP
                        (ADJP (FW de) (FW novo))
                        (NN differentiation))
                      (PP (IN in)
                        (NP (DT this) (NN system))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD Four) (JJ discrete) (NNS pieces))
        (PP (IN of)
          (NP (JJ fresh) (NN tissue))))
      (VP (VBD were)
        (VP (VBN provided)
          (PP (IN for)
            (NP
              (NP (JJ live-cell) (NN analysis))
              (PP (IN from)
                (NP
                  (NP (DT each))
                  (PP (IN of)
                    (NP
                      (ADJP
                        (ADJP
                          (NP (DT the) (NN patient) (POS 's))
                          (JJ ipsilateral))
                        (CC and)
                        (ADJP (JJ contralateral)))
                      (NNS breasts))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (DT the) (NN case))
          (PP (IN of)
            (NP (DT the) (JJ ipsilateral) (NN breast)))))
      (, ,)
      (NP (DT this) (NN tissue))
      (VP (VBD was)
        (VP (VBN provided)
          (PP (IN at)
            (S
              (VP (VBG increasing)
                (NP
                  (NP (NN distance))
                  (PP (IN from)
                    (NP (DT the) (NN tumor) (NN margin))))
                (PP (IN in)
                  (NP (CD 1) (NN cm) (NNS increments)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT All))
        (PP (IN of)
          (NP (DT these) (JJ normal) (NNS samples)))
        (VP (VBN attached)))
      (VP (CC and)
        (VP (VBD grew)
          (PP (IN in)
            (NP (PRP$ our) (NN culture) (NN system))))
        (CC and)
        (VP (VBD were)
          (VP (VBN examined)
            (PP (IN for)
              (NP
                (NP (JJ cell-to-cell) (NNS interactions))
                (CC and)
                (NP (NN morphology))))
            (PP (IN over)
              (NP
                (NP (DT a) (NN period))
                (PP (IN of)
                  (NP (CD one) (NN month)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In) (DT the) (NN context) (IN of)
        (NP
          (NP (NN breast) (NN reduction) (NN explant) (NNS cultures))
          (PP (IN from)
            (NP
              (NP (CD 22) (NNS patients))
              (PP (IN with)
                (NP (DT no) (NN breast) (NN disease)))))))
      (, ,)
      (NP (DT these) (NN patient) (NNS samples))
      (VP (VBN manifested)
        (NP
          (NP (JJ typical) (NNS mixtures))
          (PP (IN of)
            (NP (JJ fibroblastic)
              (CC and)
              (JJ epithelial) (NNS cells))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (JJ several) (NNS days))
        (PP (IN in)
          (NP
            (NP (NN culture))
            (PP (IN without)
              (NP (NN passaging)))))))
    (, ,)
    (NP (DT the) (JJ epithelial) (NNS cells))
    (VP
      (VP (VBD began)
        (S
          (VP (TO to)
            (VP (VB self-organize) (, ,)
              (S
                (ADVP (RB initially))
                (VP (VBG forming)
                  (NP
                    (NP (JJ three-dimensional) (NNS mammospheres))
                    (PRN (-LRB- -LRB-)
                      (NP (NN Figure) (NN 3A))
                      (-RRB- -RRB-)))))))))
      (, ,)
      (CC and)
      (, ,)
      (PP (IN after)
        (NP
          (NP (CD 2) (NNS weeks))
          (PP (IN in)
            (NP (NN culture)))))
      (, ,)
      (NP
        (NP
          (ADJP (RBR more) (JJ complex))
          (JJ pre-ductal) (NN linear) (NNS columns))
        (PP (IN of)
          (NP
            (NP (JJ epithelial) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (NN Figure) (NN 3B))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN tissue) (NNS explants))
        (PP (IN from)
          (NP (DT both) (NNS breasts))))
      (VP (VBD showed)
        (NP
          (NP (JJ similar) (NNS patterns))
          (PP (IN of)
            (NP (NN behavior))))
        (PRN (-LRB- -LRB-)
          (NP (NN Figure) (CD 3))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Tissue))
        (VP (VBN cultured)
          (PP (IN from)
            (NP
              (NP (DT a) (JJ contemporaneous) (JJ disease-free) (NN control))
              (CC and)
              (NP
                (NP (DT the) (JJ contralateral) (NN breast))
                (PP (IN of)
                  (NP (DT a) (JJ sporadic) (NN breast) (NN cancer) (NN patient))))))))
      (VP (VBD showed)
        (NP
          (NP (JJ similar) (NN morphology))
          (CC and)
          (NP (NN architecture)))
        (PRN (-LRB- -LRB-)
          (S
            (NP (NNS data))
            (VP (RB not) (VBN shown)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN suggested)
            (SBAR (IN that)
              (S
                (NP
                  (NP (DT the) (NN association))
                  (PP (IN between)
                    (NP
                      (NP (NN breast) (NN density))
                      (CC and)
                      (NP
                        (NP (NN risk))
                        (PP (IN of)
                          (NP (NN breast) (NN cancer)))))))
                (VP (VBZ is)
                  (ADJP (JJ due)
                    (PP (TO to)
                      (NP (VBN increased) (NN cell) (NN proliferation) (CD -LSB-29) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD One) (NN measure))
        (PP (IN of)
          (NP
            (NP (NN cell) (NN growth))
            (CC and)
            (NP (NN viability)))))
      (VP (VBZ is)
        (NP
          (NP
            (NP (DT the) (NN S-phase) (NN index))
            (PRN (-LRB- -LRB-)
              (NP (NN SPI))
              (-RRB- -RRB-)))
          (CC or)
          (NP
            (NP (DT the) (NN percentage))
            (PP (IN of)
              (NP
                (NP (NNS cells))
                (VP (VBG incorporating)
                  (NP (VBN radiolabeled) (NN thymidine))
                  (PP (IN over)
                    (NP
                      (NP (DT a) (JJ specific) (NN incubation) (NN period))
                      (PRN (-LRB- -LRB-)
                        (PP (IN in)
                          (NP (PRP$ our) (NN case)))
                        (, ,)
                        (NP (CD 2) (NNS hours))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP
        (NP (DT a) (JJ previous) (NN study))
        (PP (IN with)
          (NP (CD 22) (JJ normal)
            (NP (NN breast) (NN reduction) (NN epithelium) (NN -LSB-BRE))
            (-RRB- -RSB-) (NNS cultures)))))
    (NP (PRP we))
    (VP (VBD observed)
      (NP
        (NP (DT a) (JJ wide) (NN range))
        (PP (IN of)
          (NP (NN proliferation) (NNS rates))))
      (, ,)
      (PP (IN with)
        (NP
          (NP (NN SPI))
          (VP (VBG ranging)
            (PP (IN from)
              (NP
                (NP (DT a) (JJ low))
                (PP (IN of)
                  (NP (CD 0.2) (NN %)))))
            (PP (TO to)
              (NP
                (NP (DT a) (JJ high) (IN of) (CD 46.0) (NN %))
                (PRN (-LRB- -LRB-)
                  (NP (NN mean) (IN of) (CD 18.3) (NN ±) (CD 2.6) (NN %) (-RRB- -RRB-) (CD -LSB-30))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ contemporaneous) (NN control) (NN sample))
        (PP (IN from)
          (NP (DT a) (JJ disease-free) (NN breast) (NN reduction) (NN patient))))
      (VP (VBD had)
        (NP
          (NP (DT an) (NN SPI))
          (PP (IN of)
            (NP (CD 30.9) (NN %))))
        (, ,)
        (PP (IN at)
          (NP
            (NP (DT the) (JJR higher) (NN end))
            (PP (IN of)
              (NP (DT this) (JJ normal) (NN range)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The)
          (ADJP
            (ADJP (JJ ipsilateral))
            (CC and)
            (ADJP (JJ contralateral)))
          (NN tissue) (NNS samples))
        (PP (IN from)
          (NP (DT the) (JJ hereditary) (NN breast) (NN cancer) (NN patient))))
      (VP (VBD exhibited)
        (NP
          (NP (NN SPI))
          (PP (IN of)
            (NP
              (NP (CD 26.6) (NN %))
              (CC and)
              (NP (CD 26.2) (NN %))
              (, ,)
              (ADVP (RB respectively)))))
        (, ,)
        (S
          (VP (VBG placing)
            (NP (PRP them))
            (PP (IN at)
              (NP
                (NP (RB slightly))
                (PP (IN over)
                  (NP
                    (NP (DT the) (JJ 70th) (NN percentile))
                    (PP (IN for)
                      (NP (NN growth) (NN rate)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ contralateral) (NN sample))
        (PP (IN from)
          (NP (DT the) (JJ sporadic) (NN breast) (NN cancer) (NN patient))))
      (VP (VBD had)
        (NP
          (NP (DT an) (NN SPI))
          (PP (IN of)
            (NP (CD 17.0) (NN %))))
        (, ,)
        (S
          (VP (VBG placing)
            (NP (PRP it))
            (ADVP (RB slightly))
            (PP (IN under)
              (NP (DT the) (CD 50th) (NN percentile)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (NP
        (NP (DT all))
        (PP (IN of)
          (NP (DT these) (NN breast) (NN cancer) (NN patient) (NNS samples))))
      (VP (VBD appeared)
        (S
          (VP (TO to)
            (VP (VB grow)
              (ADVP (RB well))
              (PP (IN in)
                (NP (PRP$ our) (NN system)))
              (, ,)
              (PP (IN with)
                (NP
                  (NP (NN SPI))
                  (PP
                    (ADVP (RB well))
                    (IN within)
                    (NP
                      (NP (DT the) (NN range))
                      (PP (IN of)
                        (NP (PRP$ our) (JJ normal) (NNS samples))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN similarity))
        (PP (IN of)
          (NP
            (NP (DT the) (NN SPI) (NNS values))
            (PP (IN from)
              (NP
                (NP (DT the) (CD two) (NNS samples))
                (PP (IN from)
                  (NP (DT the) (NN BRCA1) (NN mutation) (NN carrier))))))))
      (VP (VBZ does) (RB not)
        (VP (VB appear)
          (S
            (VP (TO to)
              (VP (VB be)
                (ADJP (JJ accidental))))))))
    (: ;)
    (S
      (NP
        (NP (DT the) (NNS chances))
        (PP (IN of)
          (S
            (VP (VBG selecting)
              (NP
                (NP (CD two) (NNS samples))
                (PP (IN from)
                  (NP (DT the) (JJ normal) (NN population)))
                (PP (IN with)
                  (NP (NNS values))))
              (PP (IN as)
                (ADJP
                  (ADJP (JJ close))
                  (CC or)
                  (ADJP (JJR closer))))))))
      (VP (VBZ is)
        (ADJP (RB very) (JJ small)
          (PRN (-LRB- -LRB-)
            (NP (NN P) (JJ =) (CD 0.026))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (JJ Peripheral) (NN blood) (NNS lymphocytes))
          (CC and)
          (NP (JJ normal) (NN breast) (JJ epithelial) (NN tissue)))
        (PP (IN from)
          (NP (DT the) (JJ hereditary) (NN cancer) (NN patient))))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN cultured)
          (PP (IN for)
            (NP
              (NP (NN performance))
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ functional) (NN UDS) (NN assay))
                  (, ,)
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (VP (VBZ requires)
                        (NP (VBG living) (NNS cells))
                        (PP (IN for)
                          (NP
                            (NP (NN radiolabel) (NN incorporation))
                            (PP (IN during)
                              (NP
                                (NP (NN DNA) (NN repair) (NN synthesis))
                                (PP (VBG following)
                                  (NP (NN UV) (NN exposure)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN assay))
      (VP (VBZ is)
        (ADJP (JJ diagnostic)
          (PP (IN for)
            (NP
              (NP (DT the) (VBN inherited) (NN cancer-prone) (NN disease) (NN XP))
              (, ,)
              (SBAR
                (WHADVP (WRB where))
                (S
                  (NP (PRP it))
                  (VP (VBZ is)
                    (ADVP (RB usually))
                    (VP (VBN performed)
                      (PP (IN in)
                        (NP
                          (NP (NNS lymphocytes))
                          (CC or)
                          (NP (NN skin) (NNS fibroblasts)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (JJ novel) (NN HME) (NN tissue) (NN engineering) (NN system))
      (VP (VBZ allows)
        (S
          (NP (PRP us))
          (VP (TO to)
            (VP (VB apply)
              (NP
                (NP (DT the) (NN assay))
                (PP (TO to)
                  (NP (NN breast) (JJ epithelial) (NNS cells)))))))))
    (, ,)
    (CC and)
    (S
      (NP (PRP we))
      (VP (VBP have)
        (ADVP (RB previously))
        (VP (VBN demonstrated)
          (NP
            (NP (NN tissue-specificity))
            (PP (IN in)
              (NP
                (NP (DT the) (NN NER) (NN capacity))
                (PP (IN of)
                  (NP (DT these) (NNS cells)))))
            (PP (IN in)
              (NP
                (NP (JJ normal) (NNS samples))
                (PP (IN from)
                  (NP
                    (NP (NNS patients))
                    (VP (VBG undergoing)
                      (NP (NN breast) (NN reduction) (NN mammoplasty) (NN -LSB-30)))))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP (NN Patient) (NNS data))
      (VP (VBZ is)
        (ADVP (RB therefore))
        (VP (VBN expressed)
          (PP (JJ relative) (TO to)
            (NP
              (NP (DT the) (NN average))
              (PP (IN of)
                (NP (PRP$ our) (NN breast) (NN reduction) (NNS controls))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Analysis))
      (PP (IN of)
        (NP
          (NP (VBN cultured) (NN blood) (NNS lymphocytes))
          (PP (IN from)
            (NP (DT the) (NN patient))))))
    (VP (VBD established)
      (SBAR (IN that)
        (S
          (NP (PRP they))
          (VP (VBD had)
            (NP
              (NP
                (NP (JJ normal) (NN NER) (NN capacity))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (CD 99.6) (NN %))
                    (PP (IN of)
                      (NP
                        (NP (DT the) (NN average))
                        (PP (IN of)
                          (NP (PRP$ our)
                            (NP (CD 33) (JJ normal) (NNS samples)))))))
                  (-RRB- -RRB-)))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (CD 4))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBZ is)
        (ADVP (RB well))
        (PP (IN above)
          (NP
            (NP (DT the) (JJ cut-off)
              (ADJP (JJ established)
                (PP (IN in)
                  (NP (PRP$ our) (JJ sporadic) (NN breast) (NN cancer))))
              (NN population))
            (PRN (, ,)
              (NP
                (NP
                  (QP (RB <) (CD 70))
                  (NN %))
                (NP
                  (NP (JJ average) (JJ normal) (NN activity))
                  (, ,)
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (SBAR
                        (WHADVP (WRB when))
                        (S
                          (VP (VBN applied)
                            (PP (TO to)
                              (NP (PRP$ our)
                                (NP (NNS cases))
                                (CC and)
                                (NP (NNS controls)))))))
                      (VP (VBD yielded)
                        (NP
                          (NP (DT a)
                            (NP (JJ significant) (NNS odds))
                            (NN ratio))
                          (PP (IN of)
                            (NP (CD 37.4) (NN -LSB-31)))))))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NN trend))
        (PP (IN towards)
          (NP (NN age) (NN dependence))))
      (VP (VBD had)
        (VP (VBN been)
          (VP (VBN noted)
            (PP (IN in)
              (NP
                (NP (DT the) (NN analysis))
                (PP (IN of)
                  (S
                    (NP
                      (NP (DT the) (NN UDS) (NN data))
                      (PP (IN of)
                        (NP
                          (NP (DT the) (JJ normal) (NNS controls))
                          (PRN (-LRB- -LRB-)
                            (NP (NN P) (JJ =) (CD 0.059) (-RRB- -RRB-) (CD -LSB-30))
                            (-RRB- -RSB-)))))
                    (: ;)
                    (S
                      (NP
                        (NP (NN addition))
                        (PP (IN of)
                          (NP (DT the) (NN patient) (NN sample))))
                      (VP (VBZ supports)
                        (NP (DT this) (NN trend))))
                    (, ,)
                    (CC but)
                    (S
                      (NP (PRP it))
                      (ADVP (RB still))
                      (VP (VBZ fails)
                        (S
                          (VP (TO to)
                            (VP (VB reach)
                              (NP
                                (NP (NN significance))
                                (PRN (-LRB- -LRB-)
                                  (NP (NN P) (JJ =) (CD 0.056))
                                  (-RRB- -RRB-))))))))))))))))
    (. .)))

(
  (S
    (NP (DT The) (JJ functional) (NN NER) (NN assay))
    (VP (VBD was)
      (ADVP (RB then))
      (VP (VBN applied)
        (PP
          (PP (TO to)
            (NP
              (NP (DT the) (JJ contemporaneous) (JJ disease-free) (NN breast) (NN reduction) (NN control) (NN sample))
              (, ,)
              (NP
                (NP
                  (NP (CD one) (NN sample))
                  (NP (DT each)))
                (PP (IN from)
                  (NP
                    (NP (DT the)
                      (ADJP
                        (ADJP (JJ ipsilateral))
                        (CC and)
                        (ADJP (JJ contralateral)))
                      (NNS breasts))
                    (PP (IN of)
                      (NP (DT the) (NN patient))))))))
          (, ,)
          (CC and)
          (PP (TO to)
            (NP
              (NP (DT a) (NN sample))
              (PP (IN from)
                (NP
                  (NP (DT the) (JJ contralateral) (NN breast))
                  (PP (IN of)
                    (NP (DT an)
                      (ADJP (RB apparently) (JJ sporadic))
                      (NN breast) (NN cancer) (NN patient))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN NER))
        (PP (IN of)
          (NP (DT the) (NN BRE) (JJ non-diseased) (NN control))))
      (VP (VBD was)
        (NP (CD 1.82) (NNS times))
        (NP
          (NP (DT the) (NN average))
          (PP (IN of)
            (NP (PRP$ our) (JJ normal) (NN data) (NN set)))
          (PP
            (PP (IN for)
              (NP (DT this) (NN tissue)))
            (CC and)
            (PP (IN within)
              (NP
                (NP (DT the) (NN range))
                (PP (IN of)
                  (NP (JJ normal)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN NER) (NN capacity))
        (PP (IN of)
          (NP (DT the) (JJ ipsilateral) (NN breast) (NN epithelial) (NN sample))))
      (VP (VBD was)
        (NP
          (NP (CD 1.05) (NNS times))
          (NP
            (NP (DT the) (NN average))
            (PP (IN of)
              (NP
                (NP (PRP$ our) (NN population))
                (PP (IN of)
                  (NP (NN BRE) (NNS controls)))))))
        (, ,)
        (S
          (ADVP (RB clearly))
          (VP (VBG exhibiting)
            (NP
              (NP (DT no) (JJ overt) (NN DNA) (NN repair) (NN deficiency))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (CD 5))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ contralateral) (NN sample))
      (VP (VBD was)
        (ADJP (RB very) (JJ similar) (, ,)
          (PP (IN with)
            (NP
              (NP (DT an) (NN NER) (NN capacity))
              (PP (IN of)
                (NP
                  (NP (CD 1.17) (NNS times))
                  (ADJP (NN BRE) (JJ normal)))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (DT the) (NN NER) (NNS values))
            (PP (IN of)
              (NP
                (NP (DT these) (CD two) (NNS samples))
                (PP (IN from)
                  (NP (DT the) (JJ same) (NN patient))))))
          (VP (VBP are)
            (ADJP (JJ similar)))))
      (, ,)
      (NP (PRP they))
      (VP (VBP are) (RB not)
        (ADJP (JJ close)
          (S
            (ADVP (RB enough))
            (VP (TO to)
              (VP (VB distinguish)
                (NP (PRP themselves))
                (PP (IN as)
                  (S
                    (VP (VBG coming)
                      (PP (IN from)
                        (NP
                          (NP (DT the) (JJ same) (NN individual))
                          (PRN (-LRB- -LRB-)
                            (NP (NN P) (JJ =) (NN 0.16))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN NER) (NN capacity))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ contralateral) (NN sample))
            (PP (IN from)
              (NP (DT the) (JJ sporadic) (NN breast) (NN cancer) (NN patient))))))
      (VP (VBD was)
        (NP (CD 1.62) (NNS times))
        (NP
          (NP (DT the) (NN average))
          (PP (IN of)
            (NP (DT the) (NN BRE) (NNS controls))))
        (, ,)
        (ADVP (RB also))
        (PP (IN in)
          (NP (DT the) (JJ normal) (NN range)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (PRP$ Our) (JJR earlier) (NN analysis))
        (PP (IN of)
          (NP
            (NP (NN NER))
            (PP (IN in)
              (NP (PRP$ our) (JJ normal) (NN population))))))
      (VP (VBD revealed)
        (NP
          (NP (DT no) (NNS effects))
          (PP (IN of)
            (NP
              (NP (NN age))
              (CC or)
              (NP (NN cell) (NN proliferation))))
          (PRN (-LRB- -LRB-)
            (SBAR (IN as)
              (S
                (VP (VBN represented)
                  (PP (IN by)
                    (NP (DT the) (NN SPI))))))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT All))
        (PP (IN of)
          (NP (DT these) (JJ additional) (NN patient) (NNS samples))))
      (VP (VBP are)
        (ADJP (JJ consistent)
          (PP (IN with)
            (NP (DT those) (NNS results))))))
    (. .)))

(
  (S
    (NP (NN Discussion))))

(
  (S
    (S
      (NP
        (NP
          (QP (IN At) (JJS least) (CD two))
          (NNS types))
        (PP (IN of)
          (NP (NN breast) (NNS tumors))))
      (VP (VBP are) (RB not)
        (ADVP (RB accurately))
        (VP (VBN detected)
          (PP (IN by)
            (NP (JJ traditional) (NN screening) (NN mammography)))
          (: :)
          (NP
            (NP
              (ADJP (`` ``) (NN interval) (JJ ''))
              (NNS tumors))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (VBP arise)
                  (ADVP (RB quickly))
                  (PP (IN between)
                    (NP
                      (NP
                        (NP (NNS screenings))
                        (, ,)
                        (CC and)
                        (NP (NNS tumors)))
                      (SBAR
                        (WHNP (WP$ whose) (NN density))
                        (S
                          (VP (VBZ is) (RB not)
                            (ADJP (JJ sufficient)
                              (S
                                (VP (TO to)
                                  (VP (VB distinguish)
                                    (NP (PRP them))
                                    (PP (IN from)
                                      (NP (DT the) (JJ surrounding) (JJ normal) (NN tissue)))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ latter) (NN situation))
      (VP (VBZ is)
        (ADJP (RBR more) (JJ likely))
        (S
          (VP (TO to)
            (VP (VB occur)
              (PP (IN in)
                (NP
                  (NP (NNS women))
                  (PP (IN with)
                    (NP
                      (NP (JJ dense) (JJ normal) (NN breast) (NN tissue))
                      (, ,)
                      (SBAR
                        (WHNP (WDT which))
                        (S (, ,)
                          (PP (IN in)
                            (NP (NN turn)))
                          (, ,)
                          (VP (VBZ is)
                            (ADJP (RBR more) (JJ typical)
                              (PP (IN of)
                                (NP (JJR younger) (NNS women))))))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Thus))
    (, ,)
    (NP
      (ADJP (RB mammographically) (JJ undetectable))
      (NNS tumors))
    (VP (MD may)
      (VP (VB have)
        (NP
          (NP (DT a) (NN number))
          (PP (IN of)
            (NP
              (NP (NNS characteristics))
              (, ,)
              (PP (JJ such) (IN as)
                (NP
                  (NP
                    (NP (JJ fast) (NN growth))
                    (, ,)
                    (NP (JJ low) (NN density))
                    (, ,)
                    (NP (JJ early) (NN onset))
                    (CC and/or)
                    (NP (NN occurrence)))
                  (PP (IN in)
                    (NP
                      (NP (JJ dense) (NNS breasts))
                      (SBAR
                        (WHNP (WDT that))
                        (S
                          (VP (MD might)
                            (VP (VB distinguish)
                              (NP (PRP them))
                              (PP (IN from)
                                (NP
                                  (NP
                                    (ADJP (RB mammographically) (JJ detectable))
                                    (NNS tumors))
                                  (PP (IN in)
                                    (NP
                                      (NP (NNS terms))
                                      (PP (IN of)
                                        (NP
                                          (NP
                                            (NP (JJ molecular) (NN etiology))
                                            (CC and)
                                            (NP (JJ clinical) (NNS parameters)))
                                          (PP (IN of)
                                            (NP
                                              (NP (NN prognosis))
                                              (CC and)
                                              (NP (NN response)))))))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ present) (NN patient))
      (VP
        (VP (VBD had)
          (NP (DT an) (JJ early) (NN onset) (NN breast) (NN tumor)))
        (, ,)
        (CC but)
        (VP (VBD had)
          (NP (CC both)
            (NP
              (NP (JJ hereditary) (NN susceptibility))
              (PP (IN due) (TO to)
                (NP (PRP$ her) (NN BRCA1) (NN mutation))))
            (CC and)
            (NP (JJ dense) (NNS breasts))))
        (, ,)
        (SBAR (IN so)
          (S
            (NP (PRP$ her) (NN presentation))
            (VP (VBZ is) (RB not)
              (ADJP (JJ unusual)
                (PP (IN in)
                  (NP (DT this) (NN context)))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ is)
        (ADJP (JJ possible))
        (SBAR (IN that)
          (S
            (NP
              (NP (NN breast) (NNS tumors))
              (VP (VBN detected)
                (PP (IN by)
                  (NP (JJ complementary) (NN screening) (NNS methods)))
                (PP (IN in)
                  (NP (DT the) (JJ future)))))
            (VP (MD will)
              (VP (VB demonstrate)
                (NP (JJ unique)
                  (ADJP
                    (ADJP (JJ clinical))
                    (CC and)
                    (ADJP (JJ molecular)))
                  (NNS features)))
              (, ,)
              (SBAR
                (WHADVP (WRB when))
                (S
                  (NP (PRP it))
                  (VP (VBZ becomes)
                    (ADJP (JJ feasible)
                      (S
                        (VP (TO to)
                          (VP (VB perform)
                            (NP (JJ such) (NN screening))
                            (PP (IN in)
                              (NP (DT the) (JJ general) (NN population)))))))))))))))
    (. .)))

(
  (S
    (SBAR (IN Since)
      (S
        (NP (DT the) (NN BRCA1) (NN gene) (NN product))
        (VP (VBZ is)
          (VP (VBN known)
            (S
              (VP (TO to)
                (VP (VB play)
                  (NP (DT a) (NN role))
                  (PP (IN in)
                    (NP (NN DNA) (JJ double) (NN strand) (NN break) (NN repair) (CD -LSB-8,9))))))))
        (-RRB- -RSB-)))
    (, ,)
    (NP (PRP it))
    (VP (VBZ has)
      (VP (VBN been)
        (VP (VBN suggested)
          (SBAR (IN that)
            (S
              (NP (VBN decreased) (NN repair) (NN capacity))
              (VP (VBZ is)
                (NP
                  (NP (DT the) (NN basis))
                  (PP (IN of)
                    (NP
                      (NP (DT the) (NN breast) (NN cancer) (NN predisposition))
                      (VP (VBN observed)
                        (PP (IN in)
                          (NP (NN mutation) (NNS carriers) (CD -LSB-32-35) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PDT Such) (DT a) (JJ cellular) (NN phenotype))
      (VP (VBZ has)
        (VP (VBN been)
          (ADJP (JJ difficult)
            (S
              (VP (TO to)
                (VP (VB demonstrate)
                  (PRN (, ,)
                    (FRAG
                      (ADVP (RB however))
                      (NP (NN -LSB-36-39)))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT An) (JJ alternate) (NN possibility))
      (VP (VBZ is)
        (SBAR (IN that)
          (S
            (NP (DT the) (NN mutation))
            (VP (VBZ affects)
              (NP
                (NP (DT the)
                  (NP (NN growth))
                  (CC or)
                  (NP (NN differentiation)))
                (PP (IN of)
                  (NP (NN breast) (NN epithelial) (NNS cells))))
              (PP (IN in)
                (NP
                  (NP (DT a) (NN manner))
                  (ADJP (JJ consistent)
                    (PP (IN with)
                      (NP (NN cancer) (NN susceptibility)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN suggested)
            (SBAR (IN that)
              (S
                (NP (JJ dense) (NN breast) (NN tissue))
                (VP (VBZ is)
                  (ADJP (JJ indicative)
                    (PP (IN of)
                      (NP
                        (NP (VBN generalized) (NN hyperproliferation))
                        (SBAR
                          (WHNP (WDT that))
                          (S
                            (VP (MD might)
                              (VP (VB promote)
                                (NP (NN oncogenesis) (CD -LSB-29) (-RRB- -RSB-))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NNS findings))
      (VP (VBP show)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT all) (CD 8) (NNS samples))
              (, ,)
              (VP (VBN derived)
                (PP (IN from)
                  (NP (CC both)
                    (NP (DT the) (VBN involved))
                    (CC and)
                    (NP
                      (NP (DT the) (JJ uninvolved) (NNS breasts))
                      (PP (IN of)
                        (NP (DT a) (JJ hereditary) (NN breast) (NN cancer) (NN patient))))))))
            (VP (VBP develop)
              (NP (JJ normal) (JJ epithelial) (NN architecture))
              (PP (IN in)
                (NP (FW vitro)))
              (, ,)
              (S
                (VP (VBG implying)
                  (SBAR (IN that)
                    (S
                      (NP
                        (NP (DT the) (JJ epithelial/stromal) (-LRB- -LRB-) (JJ paracrine) (-RRB- -RRB-) (NNS interactions))
                        (ADJP (JJ necessary)
                          (PP (IN for)
                            (NP
                              (NP (DT the) (NN development))
                              (PP (IN of)
                                (NP (DT this) (JJ complex) (NN architecture)))))))
                      (VP (VBP are)
                        (ADJP
                          (ADJP (JJ intact))
                          (CC and)
                          (ADJP (JJ normal))
                          (PP (IN in)
                            (NP (NN BRCA1) (NNS heterozygotes))))
                        (PP (IN despite)
                          (NP
                            (NP (PRP$ their) (JJR greater) (NN risk))
                            (PP (IN of)
                              (NP (NN breast) (NN cancer)))))))))))))))
    (. .)))

(
  (S
    (NP (DT The) (NN SPI) (NNS results))
    (ADVP (RB also))
    (VP (VBP indicate)
      (SBAR (IN that)
        (S
          (NP (DT this) (JJ non-diseased) (JJ epithelial) (NN tissue))
          (VP
            (VP (VBZ falls)
              (PP (IN into)
                (NP
                  (NP (DT the) (JJ typical) (NN range))
                  (PP (IN of)
                    (NP (JJ normal)))
                  (PP (IN for)
                    (NP (NN BRE) (NN control) (NNS cultures))))))
            (CC and)
            (VP (VBZ is)
              (S
                (VP (VBG demonstrating)
                  (NP (JJ typical) (NN growth))
                  (PP (IN in)
                    (NP (PRP$ our) (NN HME) (NN tissue) (NN engineering) (NN system))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN NER) (NN deficiency))
      (VP (VBZ is)
        (ADVP (RBS most) (RB often))
        (VP (VBN associated)
          (PP (IN with)
            (NP
              (NP (NN XP))
              (, ,)
              (NP
                (NP (NN sensitivity))
                (PP (TO to)
                  (NP (JJ UV-induced) (NN DNA) (NN damage))))
              (CC and)
              (NP (NN skin) (NN cancer) (CD -LSB-18-21) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN NER) (NN deficiency))
        (PP (IN of)
          (NP (NN XP) (NNS patients))))
      (VP (VBZ is)
        (VP (VBN manifested)
          (PP (IN in)
            (NP (JJ other) (NNS tissues)))
          (, ,)
          (ADVP (RB however))
          (, ,)
          (SBAR (IN as)
            (S
              (VP (VBN shown)
                (PP (IN by)
                  (NP
                    (NP
                      (NP (PRP$ their) (JJ high) (JJ spontaneous) (NN frequency))
                      (PP (IN of)
                        (NP
                          (NP (NN mutation))
                          (PP (IN in)
                            (NP (NN blood) (NNS lymphocytes) (CD -LSB-40) (-RRB- -RSB-))))))
                    (CC and)
                    (NP
                      (NP (DT the) (NN occurrence))
                      (PP (IN of)
                        (NP
                          (NP (JJ other) (NNS types))
                          (PP (IN of)
                            (NP (NNS tumors) (CD -LSB-41) (-RRB- -RSB-))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN observation)
        (SBAR (IN that)
          (S
            (NP (JJ sporadic) (NN breast) (NN cancer) (NNS patients))
            (VP (VBP have)
              (NP
                (NP (JJ low) (NNS levels))
                (PP (IN of)
                  (NP (NN NER))))
              (PP (IN in)
                (NP (JJ peripheral) (NNS lymphocytes)))))))
      (VP (VBZ suggests)
        (SBAR (IN that)
          (S
            (NP (JJ sporadic) (NN breast) (NN cancer))
            (VP (VBZ is)
              (VP (VBN associated)
                (PP (IN with)
                  (NP
                    (NP
                      (ADJP (RB constitutively) (JJ low))
                      (NNS levels))
                    (PP (IN of)
                      (NP (NN NER) (NN -LSB-14-16) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (PRP$ Our) (NNS results))
        (PP (IN from)
          (NP (DT a) (JJ single) (NN patient))))
      (VP (VBP demonstrate) (, ,)
        (ADVP (RB however))
        (, ,)
        (SBAR (IN that)
          (S
            (SBAR (IN while)
              (S
                (NP
                  (NP (NN overexpression))
                  (PP (IN of)
                    (NP (NN BRCA1))))
                (VP (MD may)
                  (VP (VB enhance)
                    (NP (NN NER) (NN -LSB-22))))
                (-RRB- -RSB-)))
            (, ,)
            (NP
              (NP (NN haploinsufficiency))
              (PP (IN for)
                (NP (DT this) (NN gene))))
            (VP (VBZ does) (RB not)
              (ADVP (RB necessarily))
              (VP (VB result)
                (PP (IN in)
                  (NP (JJ detectable) (NN NER) (NN deficiency)))))))))
    (. .)))

(
  (S
    (SBAR (IN Since)
      (S
        (NP (PRP it))
        (VP (VBZ is)
          (ADJP (JJ clear))
          (SBAR (IN that)
            (S
              (NP (JJ genomic) (NN instability))
              (VP (VBZ is)
                (NP
                  (NP (DT a) (JJ necessary) (NN prerequisite))
                  (PP (IN for)
                    (NP
                      (NP (DT the) (NN completion))
                      (PP (IN of)
                        (NP
                          (NP (DT the) (JJ complex) (JJ multi-step) (JJ carcinogenic) (NN pathway) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))
                          (VP (VBN involved)
                            (PP (IN in)
                              (NP (NN breast) (NN cancer)))))))))))))))
    (, ,)
    (NP
      (NP (DT a) (JJ fundamental) (NN difference))
      (PP (IN in)
        (NP
          (NP (DT the) (NNS mechanisms))
          (PP (IN of)
            (NP
              (NP (JJ genomic) (NN instability))
              (VP (VBG arising)
                (PP (IN in)
                  (NP
                    (ADJP
                      (ADJP (JJ hereditary))
                      (CC and)
                      (ADJP (JJ sporadic)))
                    (NN breast) (NNS tumors)))))))))
    (VP (MD would)
      (VP (VB be)
        (ADJP (JJ likely)
          (S
            (VP (TO to)
              (VP (VB translate)
                (PP (IN into)
                  (NP
                    (NP
                      (ADJP (RB fundamentally) (JJ different))
                      (NNS patterns))
                    (PP (IN of)
                      (NP
                        (NP (JJ molecular) (NN pathogenesis))
                        (SBAR
                          (WHNP (WDT that))
                          (S
                            (VP (MD could)
                              (VP (NN impact)
                                (PP (IN on)
                                  (NP (JJ clinical) (NN management)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ relative) (NN NER) (NNS capacities))
        (PP (IN of)
          (NP
            (NP (NN tumor))
            (CC and)
            (NP (JJ normal) (NN tissue)))))
      (VP (MD may)
        (VP (VB have)
          (NP (JJ important) (JJ practical) (NNS implications)))))
    (. .)))

(
  (S
    (SBAR (IN If)
      (S
        (NP
          (NP (NN breast) (NNS tumors))
          (PP (IN from)
            (NP (JJ hereditary) (NNS patients))))
        (VP (VBP exhibit)
          (NP
            (NP (NN NER) (NN deficiency))
            (ADJP (JJ similar)
              (PP (TO to)
                (NP
                  (NP (DT that))
                  (VP (VBN observed)
                    (PP (IN in)
                      (NP (JJ sporadic) (NNS patients))))))))
          (, ,)
          (SBAR (IN while)
            (S
              (NP (PRP$ their) (JJ normal) (NNS tissues))
              (VP (VBP exhibit)
                (NP
                  (NP (JJ normal) (NNS levels))
                  (PP (IN of)
                    (NP
                      (NP (DT this) (NN type))
                      (PP (IN of)
                        (NP (NN DNA) (NN repair))))))))))))
    (, ,)
    (ADVP (RB then))
    (NP (DT the) (NNS tumors))
    (VP (MD would)
      (VP (VB be)
        (ADJP (JJ hypersensitive)
          (PP (TO to)
            (NP
              (NP (DT a) (NN range))
              (PP (IN of)
                (NP
                  (NP (JJ chemotherapeutic) (NNS drugs))
                  (, ,)
                  (PP (VBG including)
                    (NP
                      (NP
                        (NP (JJ alkylating) (NNS agents))
                        (PRN (-LRB- -LRB-)
                          (NP (NN cyclosphosphamide))
                          (-RRB- -RRB-)))
                      (, ,)
                      (NP
                        (NP (JJ cross-linking) (NNS agents))
                        (PRN (-LRB- -LRB-)
                          (NP (NN cis-platinum))
                          (-RRB- -RRB-)))
                      (CC and)
                      (NP
                        (NP (JJ bulky) (NN DNA) (NN adducting) (NNS agents))
                        (PRN (-LRB- -LRB-)
                          (NP (NN melphalan))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Individualization))
        (PP (IN of)
          (NP (NN chemotherapy)))
        (PP (VBN based)
          (PP (IN on)
            (NP
              (NP (DT some) (NN aspect))
              (PP (IN of)
                (NP (NN NER) (NN expression)))))))
      (VP (VBZ is)
        (VP (VBG being)
          (VP (VBN pursued)
            (PP (IN in)
              (NP
                (NP (NN colon) (CD -LSB-42) (-RRB- -RSB-))
                (, ,)
                (NP (NN testicular) (CD -LSB-43,44) (-RRB- -RSB-))
                (CC and)
                (NP
                  (NP (JJ ovarian) (NN cancer))
                  (CD -LSB-45) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (NP (NN Conclusion))))

(
  (S
    (S
      (NP
        (NP (DT This) (NN patient))
        (CC and)
        (NP (PRP$ her) (NN tumor)))
      (VP (VBP represent)
        (NP
          (NP (DT the) (NN vanguard))
          (PP (IN of)
            (NP
              (NP (DT a) (JJ new) (NN population))
              (PP (IN of)
                (NP (JJ early) (NN stage) (NN breast) (NN cancer) (NNS patients)))))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (MD will)
                (VP (VB be)
                  (ADVP (RB increasingly))
                  (VP (VBN diagnosed)
                    (SBAR (IN as)
                      (S
                        (NP
                          (NP (JJ new) (NN screening) (NNS technologies))
                          (ADJP (JJ complementary)
                            (PP (TO to)
                              (NP (NN mammography)))))
                        (VP
                          (VP (VBP are)
                            (ADJP (JJ validated)))
                          (CC and)
                          (VP (VBP become)
                            (ADJP (JJ practicable))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (VP (VBN shown)
          (SBAR (IN that)
            (S
              (NP (JJ low) (NN power) (NN MRI))
              (VP (MD can)
                (VP (VB detect)
                  (NP (DT a) (NN stage) (NN I) (NN tumor))
                  (PP (IN in)
                    (NP (JJ dense) (NN breast) (NN tissue))))))))))
    (: ;)
    (S
      (NP (DT the) (JJ same) (NN technology))
      (VP (MD can)
        (ADVP (RB also))
        (VP (NN impact)
          (PP (IN upon)
            (NP (JJ interval) (NNS tumors)))
          (PP (IN by)
            (S
              (VP
                (VP (VBG staggering)
                  (NP
                    (NP (DT the) (NN procedure))
                    (PP (IN with)
                      (NP (NN mammography)))))
                (CONJP (RB rather) (IN than))
                (VP (VBG applying)
                  (NP (PRP them))
                  (ADVP (RB coincidently)))))))))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP (PRP we))
        (VP (VBD did) (RB not)
          (VP (VB observe)
            (NP
              (NP (JJ obvious) (NNS differences))
              (PP (IN in)
                (NP
                  (NP (DT the)
                    (NP (NN growth) (NN rate))
                    (CC or)
                    (NP (NN differentiation) (NN potential)))
                  (PP (IN of)
                    (NP
                      (NP (DT the) (JJ dense) (NN breast) (NN tissue))
                      (PP (IN from)
                        (NP (DT this) (NN patient))))))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBP cannot)
      (NP (NN rule))
      (PP (IN out)
        (NP (DT the) (NN possibility)
          (SBAR (IN that)
            (S
              (NP
                (NP
                  (NP (DT some))
                  (CC or)
                  (NP (DT all)))
                (PP (IN of)
                  (NP
                    (NP (DT the) (NNS tumors))
                    (ADJP (JJ detectable)
                      (PP
                        (ADVP (RB only))
                        (IN by)
                        (NP (JJ complementary) (NN screening) (NNS procedures)))))))
              (VP (MD will)
                (VP (VB differ)
                  (PP (IN from)
                    (NP
                      (NP (DT the) (JJ present) (JJ clinical) (VBP experience))
                      (PP (IN in)
                        (NP (JJ important) (NNS ways))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (PRP$ Our) (JJ live-cell) (NN analysis))
        (VP (VBZ takes)
          (NP
            (NP (DT a) (NN step))
            (PP (IN toward)
              (S
                (VP (VBG defining)
                  (NP
                    (NP (JJ cellular) (NNS characteristics))
                    (SBAR
                      (WHNP (WDT that))
                      (S
                        (VP (MD may)
                          (VP (VB be)
                            (ADJP (JJ useful)
                              (PP (IN for)
                                (NP (NN cancer) (NN risk) (NN assessment)))))))))))))))
      (, ,)
      (CC but)
      (S
        (NP (PRP we))
        (VP (VBP are)
          (ADVP (RB only))
          (VP (VBG beginning)
            (S
              (VP (TO to)
                (VP (VB investigate)
                  (NP
                    (NP (DT the) (NNS possibilities))
                    (PP (IN of)
                      (NP (DT the) (NN system)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (MD may)
        (VP (VB be)
          (SBAR (IN that)
            (S
              (NP
                (NP (JJ different) (NN growth) (NNS conditions))
                (, ,)
                (CC or)
                (NP
                  (NP (NN induction))
                  (PP (IN with)
                    (NP
                      (ADJP
                        (ADJP (JJ genotoxic))
                        (CC or)
                        (ADJP (JJ estrogenic)))
                      (NNS agents))))
                (, ,))
              (VP (MD will)
                (VP (VB allow)
                  (PP (IN for)
                    (NP
                      (NP (DT the) (JJR greater) (NN differentiation))
                      (PP (IN of)
                        (NP
                          (NP (NN breast) (NN tissue))
                          (CC and)
                          (NP (NN tumor) (NNS behaviours)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN technique))
      (ADVP (RB also))
      (VP (VBZ allows)
        (PP (IN for)
          (NP
            (NP (DT the) (NN application))
            (PP (IN of)
              (NP (JJ functional) (NNS assays)))
            (PP (TO to)
              (NP (NN patient) (NNS samples)))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN exemplified)
              (PP (IN in)
                (NP (DT this) (NN report)))
              (PP (IN by)
                (NP
                  (NP (DT the) (NN UDS) (NN assay))
                  (PP (IN for)
                    (NP (NN NER) (NN capacity))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT Those) (NN UDS) (NNS results))
        (, ,)
        (CONJP (IN although) (IN from))
        (NP (DT a) (JJ single) (NN patient))
        (, ,))
      (VP (VBP demonstrate)
        (ADVP (RB definitively))
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the)
                (ADJP (RB constitutively) (JJ low))
                (NN NER) (NNS capacities))
              (VP (VBN reported)
                (PP (IN in)
                  (NP (JJ several) (JJ sporadic) (NN breast) (NNS populations)))))
            (VP (VBP do) (RB not)
              (VP (VB arise)
                (PP (IN as)
                  (NP
                    (NP (DT a) (JJ pleiomorphic) (NN effect))
                    (PP (IN of)
                      (NP (NN BRCA1) (NN haploinsufficency)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (NP
        (NP (DT the) (NN basis))
        (PP (IN of)
          (NP
            (NP (JJ genetic) (NN instability))
            (, ,)
            (NP
              (NP (DT a) (JJ fundamental) (NN element))
              (PP (IN in)
                (NP (NN breast) (NN carcinogenesis))))
            (, ,))))
      (VP (MD may)
        (VP (VB differ)
          (PP (IN between)
            (NP
              (ADJP
                (ADJP (JJ sporadic))
                (CC and)
                (ADJP (JJ hereditary)))
              (NN breast) (NNS tumors))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBZ results)
        (PP (IN in)
          (NP
            (NP
              (NP
                (NP (JJ different) (NNS susceptibilities))
                (PP (TO to)
                  (NP (VBG inducing) (NNS agents))))
              (, ,)
              (NP
                (NP (NNS mutations))
                (PP (IN in)
                  (NP
                    (NP (JJ different) (NNS sets))
                    (PP (IN of)
                      (NP
                        (NP (NNS oncogenes))
                        (CC and)
                        (NP (NN tumor) (NN suppressor) (NNS genes)))))))
              (, ,)
              (CC and)
              (, ,)
              (ADVP (RB ultimately))
              (, ,)
              (NP (NNS tumors)))
            (PP (IN of)
              (NP (JJ different) (JJ molecular) (NN etiology)))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (VBP express)
                  (NP
                    (ADJP
                      (ADJP (JJ different))
                      (ADJP (RB clinically) (JJ relevant)))
                    (NNS phenotypes)))))))))
    (. .)))

(
  (S
    (NP (NNS Methods))))

(
  (S
    (S
      (NP (DT The) (NN patient))
      (VP (VBD was)
        (NP
          (NP (DT a)
            (ADJP (CD 35.7) (NN year) (JJ old))
            (NN woman))
          (PP (IN with)
            (NP
              (NP (JJ strong) (NN family) (NN history))
              (PP (IN of)
                (NP (NN breast) (NN cancer))))))
        (VP (VBN recruited)
          (PP (IN into)
            (NP
              (NP (DT a) (JJ clinical) (NN trial))
              (PP (IN of)
                (NP
                  (NP (NN MRI) (NN screening))
                  (PP (IN for)
                    (NP (JJ young) (NN woman)))))))
          (PP (IN at)
            (NP
              (NP (JJ high) (NN risk))
              (PP (IN for)
                (NP (NN breast) (NN cancer)))
              (PP (IN with)
                (NP (JJ dense) (NN breast) (NN tissue) (CD -LSB-3) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Gadolinium) (NN enhancement) (NNS images))
      (VP (VBD revealed)
        (NP
          (NP (DT a) (JJ small)
            (ADJP (CD 1) (NN cm))
            (NN lesion))
          (PP (IN in)
            (NP
              (NP (DT the) (JJ upper-outer) (NN quadrant))
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ left) (NN breast))
                  (, ,)
                  (VP (VBN identified)
                    (ADVP (RB pathologically))
                    (PP (IN as)
                      (NP (DT an) (VBG infiltrating) (JJ ductal) (NN carcinoma)))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN patient))
      (VP
        (VP (VBD underwent)
          (NP
            (NP (DT a) (VBN modified) (NN radical) (NN mastectomy))
            (PP (IN of)
              (NP (DT the) (JJ left) (NN breast)))))
        (CC and)
        (VP (VBP chose)
          (S
            (VP (TO to)
              (ADVP (RB also))
              (VP (VBP undergo)
                (NP (DT a) (JJ contralateral) (JJ prophylactic) (JJ total) (NN mastectomy))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Blood))
        (CC and)
        (NP (NN tissue)))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN for)
            (NP
              (NP (NN analysis))
              (PP (IN with)
                (NP (NN consent)))))
          (PP (IN under)
            (NP
              (NP
                (NP (NNP Magee-Womens) (NNP Hospital))
                (PRN (-LRB- -LRB-)
                  (PP (IN of)
                    (NP
                      (NP (DT the) (NNP University))
                      (PP (IN of)
                        (NP (NN Pittsburgh) (JJ Medical) (NN Center)))))
                  (-RRB- -RRB-)))
              (NP (NNP IRB) (NNP #) (CD MWH-94-108)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Data))
        (PP (IN from)
          (NP (DT this) (JJ hereditary) (NN breast) (NN cancer) (NN patient))))
      (VP (VBD were)
        (VP (VBN compared)
          (PP (TO to)
            (NP
              (NP (DT that))
              (PP (IN from)
                (NP
                  (NP (CD two) (JJ additional) (NNS patients))
                  (CONJP (RB as) (RB well) (IN as))
                  (NP
                    (ADJP (RB previously) (VBN published))
                    (NNS controls)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ first) (JJ new) (NN control) (NN patient))
      (VP (VBD was)
        (NP
          (NP (DT a) (CD 20)
            (ADJP (NN year) (JJ old))
            (NNS women))
          (VP (VBG undergoing)
            (NP (NN breast) (NN reduction) (NN mammoplasty))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ second) (JJ contemporaneous) (NN control) (NN patient))
      (VP (VBD was)
        (NP
          (NP (DT a)
            (ADJP (CD 36) (NN year) (JJ old))
            (NN woman))
          (VP (VBG undergoing)
            (NP
              (NP (JJ cosmetic) (NN surgery))
              (PP (IN on)
                (NP (PRP$ her) (JJ contralateral) (NN breast))))
            (PP
              (NP (CD two) (NNS years))
              (IN after)
              (NP
                (NP (JJ successful) (NN lumpectomy))
                (S
                  (VP (TO to)
                    (VP (VB remove)
                      (NP
                        (NP (DT an)
                          (ADJP (RB apparently) (JJ sporadic))
                          (NN stage) (NN IIA) (NN breast) (NN tumor))
                        (PRN (-LRB- -LRB-)
                          (NP
                            (NP (CD 2.5) (NN cm))
                            (, ,)
                            (ADJP (JJ negative)
                              (PP (IN for)
                                (NP
                                  (NP
                                    (NP
                                      (NP (NN estrogen))
                                      (CC and)
                                      (NP (NN progesterone)))
                                    (NNS receptors))
                                  (, ,)
                                  (NP (CD 13) (NN lymph) (NNS nodes) (JJ negative))))))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP She))
      (VP (VBD had)
        (VP (VBN undergone)
          (NP
            (NP (JJ standard) (NN radiotherapy))
            (CC and)
            (NP (NN chemotherapy)))
          (PP (IN with)
            (NP
              (NP (NN adriamycin))
              (CC and)
              (NP (NN cyclophosphamide)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Histopathological) (NN analysis))
      (VP (VBD confirmed)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (NN breast) (NN tissue))
              (PP (IN from)
                (NP
                  (NP (DT both))
                  (PP (IN of)
                    (NP (DT these) (JJ control) (NNS patients))))))
            (VP (VBD was)
              (UCP
                (ADJP (JJ free)
                  (PP (IN of)
                    (NP (NN cancer))))
                (CC and)
                (PP (IN within)
                  (NP
                    (NP (DT the) (JJ acceptable) (JJ histological) (NN range))
                    (PP (IN of)
                      (NP (JJ normal)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Fresh) (NNS tissues))
        (PP (IN from)
          (NP (DT the) (NN patient))))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN within)
            (NP
              (NP (CD 5) (NNS hours))
              (PP (IN of)
                (NP (NN surgery))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP (JJ pathological) (NN evaluation)))
    (, ,)
    (NP
      (NP (JJ excess) (NN tissue))
      (VP (RB not) (VBN needed)
        (PP (IN for)
          (NP (NN diagnosis)))))
    (VP (VBD was)
      (VP (VBN placed)
        (PP (IN into)
          (NP
            (NP (NN DMEM))
            (VP (VBG containing)
              (NP
                (NP
                  (ADJP (CD 10) (NN %))
                  (JJ fetal) (NN calf) (NN serum))
                (CC and)
                (NP
                  (NP
                    (ADJP (RB 3x) (JJ antibiotic))
                    (NN antimycotic))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN Sigma))
                      (, ,)
                      (NP (NN St.) (NN Louis))
                      (, ,)
                      (NP (NN MO)))
                    (-RRB- -RRB-))))
              (PP (IN at)
                (NP (NN 4°C))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN tissue))
      (VP (VBD was)
        (ADVP (RB then))
        (VP
          (VP (VBN processed)
            (SBAR (IN as)
              (S
                (VP (VBN described)
                  (PP (IN in)
                    (NP
                      (NP (NNP Latimer) (FW et) (FW al.))
                      (NP (CD -LSB-30) (-RRB- -RSB-))))))))
          (CC and)
          (VP (VBN placed)
            (PP (IN into)
              (NP (NN culture)))
            (PP (IN on)
              (NP
                (NP (DT a) (JJ diluted) (NN form))
                (PP (IN of)
                  (NP
                    (NP (NN matrigel))
                    (PRN (-LRB- -LRB-)
                      (NP (NN 1:1))
                      (PP (IN with)
                        (NP (NN DMEM)))
                      (-RRB- -RRB-))))))
            (PP (IN in)
              (NP (DT the) (JJ novel) (NN MWRIα) (NN medium) (CD -LSB-7) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD Eight) (NNS samples))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ principal) (NN patient) (POS 's))
            (NN tissue))))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN for)
            (NP (NN culture)))
          (PP (IN after)
            (NP (JJ bilateral) (NN mastectomy) (NN surgery))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD were) (RB not)
        (ADJP (JJ able)
          (S
            (VP (TO to)
              (VP (VB obtain)
                (NP
                  (NP (DT a) (NN sample))
                  (PP (IN of)
                    (NP (PRP$ her) (NN tumor))))))))
        (, ,)
        (SBAR (IN because)
          (S
            (NP (PRP it))
            (VP (VBD was)
              (VP (VBN utilized)
                (ADVP (RB entirely))
                (PP (IN for)
                  (NP (JJ clinical) (NN diagnosis)))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD were)
        (ADJP (JJ able)
          (S
            (VP (TO to)
              (VP (VB obtain)
                (NP
                  (NP (CD 4) (NNS pieces))
                  (PP (IN of)
                    (NP
                      (ADJP (RB histologically) (JJ normal))
                      (JJ non-tumor) (JJ adjacent) (NN tissue))))
                (PP (IN at)
                  (NP
                    (NP (VBG increasing)
                      (ADJP (CD 1) (NN cm))
                      (NNS intervals))
                    (PP (IN from)
                      (NP
                        (NP (DT the) (NN tumor) (NN margin))
                        (PP (IN from)
                          (NP (PRP$ her) (JJ left) (-LRB- -LRB-) (JJ ipsilateral) (-RRB- -RRB-) (NN breast)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (PRP we))
      (VP (VBD obtained)
        (NP
          (NP (CD 4) (JJ similar) (NNS pieces))
          (PP (IN of)
            (NP (JJ fresh) (NN tissue)))
          (PP (IN from)
            (NP (PRP$ her) (JJ contralateral) (NN breast))))))
    (. .)))

(
  (S
    (S
      (NP (DT All))
      (VP (VBD were)
        (VP (VBN placed)
          (PP (IN into)
            (NP (JJ primary) (NN explant) (-LRB- -LRB-) (NN HME) (-RRB- -RRB-) (NN culture))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP
          (NP (NN analysis))
          (PP (IN of)
            (NP
              (NP (NN cell) (NN growth))
              (CC and)
              (NP
                (ADJP (FW in) (FW vitro))
                (NN differentiation))))))
      (, ,)
      (NP (NNS explants))
      (VP (VBD were)
        (VP
          (VP (VBN cultured))
          (CC and)
          (VP (VBN imaged)
            (NP (DT every) (JJ second) (NN day))
            (S
              (VP (VBG using)
                (NP
                  (NP (DT a) (JJ digital) (NN Hamamatsu) (NN Orca) (NN camera))
                  (PP (IN for)
                    (NP (CD 30–60) (NNS days))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Images))
      (VP (VBD were)
        (VP (VBN analyzed)
          (PP (IN on)
            (NP
              (NP (DT a) (JJ Macintosh) (NN G4) (NN computer))
              (VP (VBG using)
                (NP
                  (NP (JJ QED) (JJ imaging) (NN software))
                  (PRN (-LRB- -LRB-)
                    (FRAG
                      (NP (NNS Media) (NN Cybernetics))
                      (, ,)
                      (NP (NNP Inc.))
                      (, ,)
                      (NP (NN Silver) (NN Spring))
                      (, ,)
                      (NP (NN MD)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Breast) (NN reduction) (NN mammoplasty) (NNS tissues))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN from)
            (NP
              (NP (NNS patients))
              (VP (NNS ages)
                (NP (NN 20–70))
                (PP (IN at)
                  (NP
                    (NP (NNP Magee-Womens) (NNP Hospital))
                    (PP (IN under)
                      (NP (DT the) (JJ above) (NN IRB)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (JJ neighboring) (NN piece))
        (PP (IN of)
          (NP
            (NP (NN mammoplasty) (NN tissue))
            (PRN (-LRB- -LRB-)
              (PP (IN from)
                (NP (DT the) (JJ same) (CD 0.25) (NN cm2) (NN sample)))
              (-RRB- -RRB-))))
        (PP (TO to)
          (NP
            (NP (DT that))
            (VP (VBN placed)
              (PP (IN into)
                (NP (JJ primary) (NN culture)))))))
      (VP (VBD was)
        (UCP
          (ADJP (JJ fixed))
          (CC and)
          (VP (VBN processed)
            (PP (IN in)
              (NP (NN paraffin)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS sections))
      (VP (VBD were)
        (VP (VBN examined)
          (PP (IN by)
            (NP
              (NP (DT a) (NN pathologist))
              (S
                (VP (TO to)
                  (VP (VB verify)
                    (NP
                      (NP (DT the) (JJ histological) (NNS features))
                      (CC and)
                      (NP
                        (NP (NN normality))
                        (PP (IN of)
                          (NP (DT the) (NN tissue)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Breast) (NN tissue))
      (VP (VBD was)
        (VP (VBN processed)
          (PP (IN as)
            (NP
              (ADJP (RB previously) (VBN described))
              (NN -LSB-30)))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (NN Tissue))
      (VP (VBD was)
        (VP
          (VP (VBN rinsed)
            (NP
              (NP (CD three) (NNS times))
              (PP (IN in)
                (NP
                  (NP (NNS PBS))
                  (VP (VBG containing)
                    (NP (NNS antibiotics)))))))
          (, ,)
          (VP (VBN disaggregated))
          (CC and)
          (VP (VBN placed)
            (PP (IN into)
              (NP (NN MWRIα) (NN medium) (CD -LSB-7) (-RRB- -RSB-)))
            (PP (IN on)
              (NP
                (NP (DT a) (JJ thin) (NN coat))
                (PP (IN of)
                  (NP (NN matrigel)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Peripheral) (NN blood) (NNS lymphocytes))
        (PRN (-LRB- -LRB-)
          (NP (NNS PBLs))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN with)
            (NP (NN consent)))
          (PP
            (PP (IN from)
              (NP (JJ normal) (JJ healthy) (NN control) (NNS subjects)))
            (NP
              (NP (NNS ages) (CD 20–50))
              (NP
                (NP (NNP working))
                (PP (IN at)
                  (NP
                    (NP (NNP Magee-Womens) (NNP Hospital))
                    (CC or)
                    (NP (NNS students))))
                (PP (IN at)
                  (NP
                    (NP (DT the) (NNP University))
                    (PP (IN of)
                      (NP (NN Pittsburgh)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Foreskin) (NN fibroblast))
          (PRN (-LRB- -LRB-)
            (NP (NN FF))
            (-RRB- -RRB-)))
        (NN tissue))
      (VP (VBD was)
        (VP
          (VP (VBN obtained)
            (PP (IN as)
              (NP
                (NP (JJ discarded) (NN tissue))
                (PP (IN from)
                  (NP (JJ newborn) (NNS infants)))))
            (PP (IN after)
              (NP (NN circumcision))))
          (CC and)
          (VP (VBN utilized)
            (PP (IN between)
              (NP (NNS passages) (CD 7)
                (CC and)
                (CD 10)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (JJ control) (NNS populations))
      (VP (VBP have)
        (VP (VBN been)
          (ADVP (RB previously))
          (VP (VBN described)
            (PP (IN in)
              (NP (JJR greater) (NN detail) (CD -LSB-30,46) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Breast) (NN tissue) (NNS samples))
        (PP (IN from)
          (NP (DT the) (CD two) (JJ new) (NN control) (NNS patients))))
      (VP (VBD were)
        (VP (VBN processed)
          (PP (IN in)
            (NP (DT the) (JJ same) (NN manner))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Primary) (NNS cultures))
        (PP (IN of)
          (NP (JJ mammary) (NN tissue)))
        (, ,)
        (VP (VBN established)
          (NP (CD 10–14) (NNS days)))
        (, ,))
      (VP (VBD were)
        (VP (VBN labeled)
          (PP (IN with)
            (NP (NN 3H-thymidine)))
          (PP (IN for)
            (NP
              (NP (DT a) (NN period))
              (PP (IN of)
                (NP (CD 2) (NNS hours)))
              (VP
                (VP (VBN followed)
                  (PP (IN by)
                    (NP
                      (NP (DT a) (NN chase))
                      (PP (IN with)
                        (NP (JJ cold) (NN thymidine)))))
                  (PP (IN for)
                    (NP (CD 2) (NNS hours))))
                (CC and)
                (VP
                  (ADVP (RB then))
                  (VBN processed)
                  (PP (IN for)
                    (NP (NN autoradiography))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (DT a)
          (ADJP (CD 10–12) (NN day))
          (NN exposure)))
      (, ,)
      (NP (NNS slides))
      (VP (VBD were)
        (VP
          (VP (VBN processed))
          (CC and)
          (VP (VBN analyzed)
            (PP (IN by)
              (NP
                (NP (CD two)
                  (ADJP
                    (ADJP (JJ independent))
                    (, ,)
                    (ADJP (JJ blinded)))
                  (NNS scorers))
                (SBAR
                  (WHNP (WP who))
                  (S
                    (VP (VBD evaluated)
                      (NP
                        (NP (DT the) (NN tissue) (NNS samples))
                        (PP (IN for)
                          (NP
                            (NP (DT the) (NN percentage))
                            (PP (IN of)
                              (NP (NNS cells))))))
                      (PP (IN in)
                        (NP
                          (NP (NN S) (NN phase))
                          (-LRB- -LRB-)
                          (VP (VBN characterized)
                            (PP (IN by)
                              (NP
                                (NP (JJ complete) (NN coverage))
                                (PP (IN of)
                                  (NP (DT the) (NN nucleus)))
                                (PP (IN with)
                                  (NP (NN silver) (NNS grains))))))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN NER))
      (VP (VBD was)
        (VP (VBN measured)
          (PP (IN by)
            (NP
              (NP (NN autoradiography))
              (PP (IN of)
                (NP (JJ unscheduled) (NN DNA) (NN synthesis)))))
          (PP (IN after)
            (NP (NN UV) (NN damage)))
          (PRN (-LRB- -LRB-)
            (NP (NNP UDS) (-RRB- -RRB-) (CD -LSB-47,48))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (DT a) (NN total))
        (PP (IN of)
          (NP
            (NP (CD 10–14) (NNS days))
            (PP (IN in)
              (NP (NN culture)))))))
    (, ,)
    (PP (IN without)
      (NP (NN passaging)))
    (, ,)
    (NP (NNS cultures))
    (VP (VBD were)
      (ADJP (JJ irradiated)
        (PP (IN with)
          (NP
            (NP (NN UV) (NN light))
            (PP (IN at)
              (NP (CD 254) (NN nm))))))
      (PP (IN at)
        (NP
          (NP (DT a) (JJ mean) (NN fluence))
          (PP (IN of)
            (NP (CD 1.2) (NN Joules/m2)))
          (PP (IN for)
            (NP (CD 12) (NNS seconds)))))
      (PP (IN in)
        (NP
          (NP (DT the) (NN absence))
          (PP (IN of)
            (NP (NN culture) (NN medium)))))
      (, ,)
      (PP (IN for)
        (NP
          (NP (DT a) (JJ total) (NN dose))
          (PP (IN of)
            (NP (CD 14) (NN J/m2))))))
    (. .)))

(
  (S
    (S
      (NP (DT Each) (NN sample))
      (VP (VBD was)
        (VP (VBN represented)
          (PP (IN by)
            (NP
              (QP (IN at) (JJS least) (CD two))
              (NN chamber) (NNS slides))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD One) (NN chamber))
        (PP (IN of)
          (NP (DT each) (JJ 2-chamber) (NN slide))))
      (VP (VBD was)
        (VP (VBN shielded)
          (PP (IN from)
            (NP (DT the) (NN UV) (NN dose)))
          (S
            (VP (TO to)
              (VP (VB be)
                (VP (VBN used)
                  (PP (IN as)
                    (NP (DT an) (JJ unirradiated) (JJ control) (NN sample))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Primary) (NNS cultures))
      (VP (VBD had) (RB not)
        (VP
          (VP (VBD reached)
            (NP (NN confluence)))
          (CC and)
          (VP (VBD were)
            (ADVP (RB still))
            (ADJP (RB actively) (VBG growing))
            (PP (IN at)
              (NP
                (NP (DT the) (NN time))
                (S
                  (NP (DT the) (NN UDS) (NN assay))
                  (VP (VBD was)
                    (VP (VBN performed))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Control) (NNS FF))
      (VP (VBD were)
        (VP (VBN plated)
          (PP
            (NP
              (QP (RB subconfluently) (CD 2))
              (NNS days))
            (IN before)
            (NP (DT the) (NN UDS) (NN assay)))
          (S
            (VP (TO to)
              (VP (VB insure)
                (SBAR (IN that)
                  (S
                    (NP (PRP they))
                    (ADVP (RB also))
                    (VP (VBD were)
                      (PP (RB not) (IN in)
                        (NP
                          (NP (DT a) (JJ quiescent) (NN state))
                          (VP (VBN brought)
                            (PRT (IN on))
                            (PP (IN by)
                              (NP (NN confluence)))))))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP (NN UV) (NN exposure)))
    (, ,)
    (NP (DT all) (NNS cultures))
    (VP (VBD were)
      (VP (VBN incubated)
        (PP (IN in)
          (NP
            (NP (NN medium))
            (VP (VBN supplemented)
              (PP (IN with)
                (NP
                  (NP
                    (NP (CD 10) (NN μCi) (NN ml) (NN -LSB-3H) (-RRB- -RSB-) (NN methyl-thymidine))
                    (PRN (-LRB- -LRB-)
                      (NP (CD ~80) (NN Ci) (NN mmol-1))
                      (-RRB- -RRB-)))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP PerkinElmer) (NN Life) (NNP Sciences) (, ,) (NNP Boston) (, ,) (NNP MA))
                    (-RRB- -RRB-)))))))
        (PP (IN for)
          (NP
            (NP (CD 2) (NNS hours))
            (PP (IN at)
              (NP (NN 37°C)))))))
    (. .)))

(
  (S
    (S
      (NP (NN Labeling) (NN medium))
      (VP (VBD was)
        (ADVP (RB then))
        (VP
          (VP (VBN replaced)
            (PP (IN with)
              (NP
                (NP (JJ unlabeled) (NN chasing) (NN medium))
                (VP (VBG containing)
                  (NP
                    (NP
                      (ADJP (CD 10-3) (NN M))
                      (JJ non-radioactive) (NN thymidine))
                    (PRN (-LRB- -LRB-)
                      (NP (NN Sigma))
                      (-RRB- -RRB-)))))))
          (CC and)
          (VP (VBN incubated)
            (PP (IN for)
              (NP
                (NP (DT a) (JJ further) (CD 2) (NNS hours))
                (PP (TO to)
                  (NP
                    (NP (JJ clear) (JJ radioactive) (VB label))
                    (PP (IN from)
                      (NP (DT the) (JJ intracellular) (NN nucleotide) (NNS pools)))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (NN incubation))
        (PP (IN in)
          (NP (DT the) (JJ post-labeling) (NN medium)))))
    (, ,)
    (NP (NNS cells))
    (VP (VBD were)
      (UCP
        (ADJP (JJ fixed)
          (PP (IN in)
            (NP
              (NP (JJ 1X) (NN SSC))
              (, ,)
              (NP
                (NP
                  (ADJP
                    (NP (CD 33) (NN %))
                    (JJ acetic))
                  (NN acid))
                (PP (IN in)
                  (NP
                    (NP (NN ethanol))
                    (, ,)
                    (VP (VBN followed)
                      (PP (IN by)
                        (NP
                          (ADJP (CD 70) (NN %))
                          (NN ethanol))))))))))
        (CC and)
        (ADVP (RB finally))
        (VP (VBN rinsed)
          (PP (IN in)
            (NP
              (ADJP (CD 4) (NN %))
              (JJ perchloric) (NN acid)))
          (PP (IN over)
            (NP
              (NP (NN night))
              (PP (IN at)
                (NP (NN 4°C))))))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS slides))
      (VP (VBD were)
        (VP
          (VP
            (VP (VBN dried))
            (CC and)
            (ADVP (RB subsequently))
            (VP (VBD dipped)
              (PP (IN in)
                (NP
                  (NP (JJ photographic) (NN emulsion))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Kodak) (NN type) (NN NTB2))
                    (-RRB- -RRB-))))))
          (CC and)
          (VP (VBN exposed)
            (PP (IN for)
              (NP
                (QP (CD 10) (TO to) (CD 14))
                (NNS days)))
            (PP (IN in)
              (NP
                (NP (JJ complete) (NNS darkness))
                (PP (IN at)
                  (NP (NN 4°C)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN length))
        (PP (IN of)
          (NP
            (NP (NN exposure))
            (PP (IN of)
              (NP (NN emulsion))))))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN in)
            (NP (DT each) (NN experiment)))
          (PP (IN by)
            (S
              (VP (VBG preparing)
                (NP (JJ FF) (`` ``) (NN tester) (NN '') (NNS slides))))))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN After)
          (NP (CD 10–12) (NNS days)))
        (NP (DT these) (NN tester) (NNS slides))
        (VP (VBD were)
          (VP (VBN developed))))
      (CC and)
      (S
        (NP (NN grain) (NN counting))
        (VP (VBD was)
          (VP (VBN performed)))))
    (. .)))

(
  (S
    (S
      (SBAR (IN If)
        (S
          (NP
            (NP (DT the) (NNS nuclei))
            (PP (IN over)
              (NP (DT the) (NN foreskin) (NNS fibroblasts))))
          (VP (VBD averaged)
            (NP
              (QP (CD 50)
                (CC or)
                (JJR more))
              (NNS grains))
            (PP (IN per)
              (NP (NN nucleus))))))
      (, ,)
      (NP
        (NP (RB then) (DT the) (NN rest))
        (PP (IN of)
          (NP (DT the) (JJ experimental) (NNS slides))))
      (VP (VBD were)
        (VP (VBN developed))))
    (. .)))

(
  (S
    (S
      (SBAR (IN If)
        (S
          (NP (DT the) (NN grain) (NN count))
          (VP (VBD was)
            (PP (IN below)
              (NP (DT this) (NN level))))))
      (, ,)
      (NP (DT the) (VBG remaining) (NNS slides))
      (VP (VBD were)
        (ADJP (JJ left)
          (S
            (VP (TO to)
              (VP (VBP expose)
                (ADVP
                  (NP (CD 1–3) (NNS days))
                  (RBR longer))
                (PP (IN before)
                  (S
                    (VP (VBG being)
                      (VP (VBN developed)))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (JJ photographic) (NN development))
        (PP (IN of)
          (NP (NN emulsion)))))
    (, ,)
    (NP (DT all) (NNS slides))
    (VP (VBD were)
      (VP (VBN stained)
        (PP (IN with)
          (NP (NN Giemsa)))
        (, ,)
        (ADVP (RB then))
        (VP (VBN examined)
          (PP (IN at)
            (NP
              (NP (DT a) (JJ total) (NN magnification))
              (PP (IN of)
                (NP (NN 1000X)))))
          (PP (IN on)
            (NP
              (NP (DT a) (NNP Zeiss) (NNP Axioskop))
              (PRN
                (PP (IN under)
                  (NP
                    (NP (NN oil) (NN emersion))
                    (PP (IN for)
                      (NP
                        (NP (NNS grains))
                        (ADJP (JJ located)
                          (ADVP (RB immediately)))))
                    (PP (IN over)
                      (NP
                        (NP (DT the) (NNS nuclei))
                        (PP (IN of)
                          (NP
                            (NP (NN non-S) (NN phase))
                            (NNS cells)))))))
                (NP (CD -LSB-48))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (JJ Local) (NN background) (NN grain) (NNS counts))
        (VP (VBD were)
          (VP (VBN evaluated)
            (PP (IN in)
              (NP
                (NP (DT each) (JJ microscopic) (NN field))
                (PP (IN over)
                  (NP (DT an) (NN area)
                    (NP (DT the) (JJ same) (NN size))))))
            (PP (IN as)
              (NP (DT a) (JJ representative) (NN nucleus))))))
      (, ,)
      (CC and)
      (S
        (NP (DT this) (NN total))
        (VP (VBD was)
          (VP (VBN subtracted)
            (PP (IN from)
              (NP
                (NP (DT the) (NN grain) (NN count))
                (PP (IN of)
                  (NP (DT each) (NN nucleus)))
                (PP (IN in)
                  (NP (DT that) (NN field)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ average) (NN number))
        (PP (IN of)
          (NP (NNS grains)))
        (PP (IN per)
          (NP (NN nucleus))))
      (VP (VBD was)
        (VP (VBN quantified)
          (PP (IN for)
            (NP
              (NP (DT each) (NN side))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN chamber) (NN slide))
                  (, ,)
                  (ADJP (CC both)
                    (ADJP (JJ unirradiated))
                    (CC and)
                    (ADJP (JJ irradiated))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ final) (NN NER) (NN value))
        (PP (IN for)
          (NP (DT each) (NN slide))))
      (VP (VBD was)
        (VP (VBN calculated)
          (PP (IN by)
            (S
              (VP (VBG subtracting)
                (NP
                  (NP (DT the) (JJ unirradiated) (JJ mean))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NNS grains))
                      (PP (IN per)
                        (NP (NN nucleus))))
                    (-RRB- -RRB-)))
                (PP (IN from)
                  (NP
                    (NP (DT the) (JJ irradiated) (NN mean))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NNS grains))
                        (PP (IN per)
                          (NP (NN nucleus))))
                      (-RRB- -RRB-)))))))
          (, ,)
          (PP (IN after)
            (NP
              (NP (DT the) (JJ initial) (NN subtraction))
              (PP (IN of)
                (NP (JJ local) (NN background)))
              (PP (IN in)
                (NP (DT each) (NN field))))))))
    (. .)))

(
  (S
    (S
      (NP (NN NER))
      (VP (VBD was)
        (ADVP (RB initially))
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT a) (NN percentage))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN activity))
                  (PP (IN of)
                    (NP
                      (ADJP (RB concurrently) (VBN analyzed))
                      (NN FF))))))))))
    (. .)))

(
  (S
    (S
      (NP (CD Four) (JJ FF) (NNS slides))
      (VP (VBD were)
        (VP (VBN scored)
          (PP (IN per)
            (NP (NN experiment)))
          (, ,)
          (PP (IN by)
            (NP
              (NP (DT an) (NN average))
              (PP (IN of)
                (NP
                  (NP (CD three))
                  (VBZ counters))))))))
    (. .)))

(
  (S
    (S
      (NP (CD 200) (NNS nuclei))
      (VP (VBD were)
        (VP (VBN counted)
          (PP (IN per)
            (NP (NN slide)))
          (, ,)
          (PP (IN for)
            (NP
              (NP (DT a) (NN total))
              (PP (IN of)
                (NP (CD 800)))))
          (, ,)
          (PP (IN with)
            (NP
              (NP (DT an) (NN average))
              (PP (IN of)
                (NP (CD 61.6) (NN grains/nucleus))))))))
    (. .)))

(
  (S
    (S
      (NP (CD Six) (NNS slides))
      (VP (VBD were)
        (VP (VBN evaluated)
          (PP (IN for)
            (NP
              (NP
                (NP (DT the) (NN patient) (POS 's))
                (NN PBL) (NN sample))
              (, ,)
              (NP
                (NP (CD two))
                (PP (IN by)
                  (NP
                    (NP (DT each))
                    (PP (IN of)
                      (NP
                        (NP (CD three))
                        (VBZ counters)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT An) (NN average))
        (PP (IN of)
          (NP (NN 195) (NNS nuclei))))
      (VP (VBD were)
        (VP (VBN scored)
          (PP (IN per)
            (NP
              (NP (NN slide))
              (PRN (-LRB- -LRB-)
                (PP (IN for)
                  (NP
                    (NP (DT a) (NN total))
                    (PP (IN of)
                      (NP (RB almost) (CD 1200)))))
                (-RRB- -RRB-))))
          (, ,)
          (PP (IN with)
            (NP
              (NP (DT an) (NN average))
              (PP (IN of)
                (NP (CD 7.5) (NN grains/nucleus))))))))
    (. .)))

(
  (S
    (S
      (NP (CD Four) (NNS slides))
      (VP (VBD were)
        (VP (VBN counted)
          (PP (IN for)
            (NP
              (NP (DT the) (JJ contemporaneous) (NN breast) (NN reduction) (NN control))
              (, ,)
              (NP (CD two)
                (NP (DT each)))))
          (PP (IN by)
            (NP
              (NP (CD two))
              (VBZ counters))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBD were)
        (NP
          (NP (DT an) (NN average))
          (PP (IN of)
            (NP (CD 200) (NNS nuclei)))
          (PP (IN per)
            (NP
              (NP (NN slide))
              (CC and)
              (NP (CD 14.1) (NN grains/nucleus)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (CD Six) (NNS slides))
        (VP (VBD were)
          (VP (VBN scored)
            (PP (IN from)
              (NP
                (NP (DT the) (NN patient) (POS 's))
                (JJ ipsilateral) (NN breast) (NN tissue) (NN sample)))
            (, ,)
            (S
              (NP
                (NP (CD two))
                (PP (IN by)
                  (NP
                    (NP (DT each))
                    (PP (IN of)
                      (NP (CD three) (JJ independent) (VBZ counters))))))))))
      (, ,)
      (CC and)
      (S
        (NP (CD five) (NNS slides))
        (VP (VBD were)
          (VP (VBN counted)
            (PP (IN from)
              (NP (DT the) (JJ contralateral) (NN sample)))
            (, ,)
            (ADVP (RB again))
            (PP (IN by)
              (NP (CD three) (JJ independent) (VBZ counters)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT An) (NN average))
        (PP (IN of)
          (NP
            (QP (RB just) (IN over) (CD 100))
            (NNS nuclei))))
      (VP (VBD were)
        (VP (VBN evaluated)
          (PP (IN per)
            (NP (NN slide)))
          (PP (IN for)
            (NP (DT each) (NN sample)))
          (, ,)
          (PP
            (PP (IN for)
              (NP
                (NP (DT a) (NN total))
                (PP (IN of)
                  (NP
                    (QP (RB almost) (CD 600))
                    (NNS nuclei)))))
            (PP (IN for)
              (NP (DT the) (JJ ipsilateral) (NN sample)))
            (CC and)
            (PP (IN over)
              (NP (CD 500)))
            (PP (IN for)
              (NP (DT the) (JJ contralateral) (NN sample)))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (NP (DT the) (NN NER) (NNS capacities))
          (VP (VBP indicate))))
      (, ,)
      (NP (DT these) (NNS samples))
      (VP (VBD had)
        (NP
          (ADJP (RB very) (JJ similar))
          (NNS counts)))
      (: ;)
      (NP
        (NP
          (NP
            (QP (RB about) (CD 35))
            (NN grains/nucleus))
          (PP (IN for)
            (NP (DT the) (JJ ipsilateral) (NN sample))))
        (CC and)
        (NP
          (NP (CD 28) (NN grains/nucleus))
          (PP (IN for)
            (NP (DT the) (JJ contralateral) (NN sample))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Finally))
      (, ,)
      (NP (CD four) (NNS slides))
      (VP (VBD were)
        (VP (VBN counted)
          (PP (IN from)
            (NP
              (NP (DT the) (JJ contralateral) (NN sample))
              (PP (IN of)
                (NP (DT a) (JJ sporadic) (NN breast) (NN cancer) (NN patient)))))
          (, ,)
          (PP (IN by)
            (NP
              (NP (CD three))
              (VBZ counters))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBD were)
        (NP
          (NP
            (NP (DT an) (NN average))
            (PP (IN of)
              (NP (CD 200) (NNS nuclei)))
            (PP (IN per)
              (NP (NN slide))))
          (CC and)
          (NP
            (NP (CD 29.4) (NNS grains))
            (PP (IN per)
              (NP (NN nucleus)))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP
            (VP (VB ensure)
              (NP (NN accuracy)))
            (CC and)
            (VP (VB guard)
              (PP (IN against)
                (NP (NN transcription) (NNS errors)))))))
      (, ,)
      (NP
        (NP (NN raw) (NN grain) (NNS counts))
        (PP (IN from)
          (NP (DT the) (NN UDS) (NN assay))))
      (VP (VBD were)
        (VP (VBN processed)
          (ADVP (RB independently))
          (PP (IN in)
            (NP (NN duplicate)))
          (, ,)
          (ADVP (RB once))
          (S
            (VP (VBG using)
              (NP
                (NP (NN StatView))
                (PRN (-LRB- -LRB-)
                  (NP (NN version) (CD 5.0.1)))))))))
    (, ,)))

(
  (S
    (NP
      (NP (NN SAS) (NN Institute))
      (, ,)
      (NP
        (NP (NNP Inc.) (, ,) (NNP Cary))
        (PRN (, ,)
          (NP (CD NC))
          (-RRB- -RRB-)))
      (, ,)
      (CC and)
      (ADVP (RB once)))
    (VP (VBG using)
      (NP
        (NP (DT the) (NNS Data) (NN Analysis)
          (NP (NNP Toolpack)))
        (PP (IN of)
          (NP
            (NP (DT the)
              (NP (NN Excel) (CD 2001) (NN spreadsheet))
              (NN program))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN Microsoft) (NNP Corp.))
                (, ,)
                (NP (NNP Redmond) (, ,) (NNP WA)))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ final) (NN count))
        (PP (IN from)
          (NP
            (NP
              (NP (NNS slides))
              (PP (IN of)
                (NP (DT the) (JJ same) (NN cell) (NN type)))
              (PP (IN within)
                (NP (DT the) (JJ same) (NN experiment))))
            (CC and)
            (NP (VBN developed)
              (NP (DT the) (JJ same) (NN day))))))
      (VP (VBD were)
        (VP
          (VP (VBN averaged)
            (ADVP (RB together)))
          (CC and)
          (VP (VBN expressed)
            (PP (IN as)
              (NP
                (NP (DT a) (NN percentage))
                (PP (IN of)
                  (NP
                    (ADJP (RB concurrently) (VBN analyzed))
                    (NN FF)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN normalized)
          (PP (IN by)
            (NP
              (NP (NN comparison))
              (PP (TO to)
                (NP
                  (NP (DT the) (NN average))
                  (PP (IN for)
                    (NP (DT the) (NN tissue) (NN type) (NN control) (NN population) (CD -LSB-48)))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (NP (VBG Competing) (NNS interests))))

(
  (S
    (S
      (NP (DT The) (NNS authors))
      (VP (VB declare)
        (SBAR (IN that)
          (S
            (NP (PRP they))
            (VP (VBP have)
              (NP (DT no) (VBG competing) (NNS interests)))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Authors) (POS '))
      (NNS contributions))))

(
  (S
    (S
      (NP (NN JJL))
      (VP (VBD conceived)
        (PP (IN of)
          (NP (DT the) (NN study)))
        (, ,)
        (S
          (VP
            (VP (VBN executed)
              (NP (PRP it)))
            (, ,)
            (CC and)
            (VP (VBN drafted)
              (NP (DT the) (NN manuscript)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS WSR))
        (VP
          (VP (VBN recruited))
          (CC and)
          (VP (VBN consented)
            (NP (DT the) (NN patient))))
        (, ,))
      (VP (VBD provided)
        (NP
          (NP (JJ clinical) (NNS samples))
          (CC and)
          (NP (NN information)))))
    (. .)))

(
  (S
    (S
      (NP (NN JMJ))
      (VP
        (VP (VBD evaluated)
          (NP (DT the) (NN UDS) (NN assay)))
        (CC and)
        (VP (VBD analyzed)
          (NP (DT the) (NNS data)))))
    (. .)))

(
  (S
    (S
      (NP (NNS AKS))
      (VP (VBD performed)
        (NP
          (NP (DT the) (JJ histopathological) (NN analysis))
          (PP (IN of)
            (NP (DT the) (NN tissue))))))
    (. .)))

(
  (S
    (S
      (NP (NN VGV))
      (VP (VBD participated)
        (PP (IN in)
          (NP (DT the)
            (NP (NN study) (NN design))
            (CC and)
            (NP (NN data) (NN interpretation))))))
    (. .)))

(
  (S
    (S
      (NP (NN SGG))
      (VP
        (VP (VBD participated)
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP
                  (NP (NN design))
                  (CC and)
                  (NP (NN coordination))))
              (PP (IN of)
                (NP (DT the) (NN study))))))
        (CC and)
        (VP (VBD helped)
          (PP (TO to)
            (NP (JJ draft) (DT the) (NN manuscript))))))
    (. .)))

(
  (S
    (NP (NN Pre-publication) (NN history))))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ pre-publication) (NN history))
        (PP (IN for)
          (NP (DT this) (NN paper))))
      (VP (MD can)
        (VP (VB be)
          (VP (VBN accessed)
            (ADVP (RB here))))))
    (: :)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (S
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP (NN Pedigree))
        (PP (IN of)
          (NP (DT the) (NN patient)))
        (-LRB- -LRB-)
        (VP (VBN indicated)
          (PP (IN by)
            (NP (NN arrow))))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (PRP She))
          (, ,)
          (NP
            (NP (CD one) (JJ maternal) (NN aunt))
            (CC and)
            (NP (CD one) (JJ maternal) (NN cousin))))
        (VP (VBD had)
          (NP
            (NP (NN breast) (NN cancer))
            (VP (VBN diagnosed)
              (PP (IN at)
                (NP (CD 36) (, ,) (CD 44)
                  (CC and)
                  (CD 41) (NNS years) (JJ old)))))
          (, ,)
          (ADVP (RB respectively))
          (, ,)
          (SBAR (IN as)
            (S
              (VP (VBN indicated)
                (PP (IN by)
                  (NP (DT the) (JJ half-filled) (NNS symbols))))))))
      (, ,)
      (CC and)
      (S
        (NP (PRP$ her) (NN aunt))
        (VP (VBD died)
          (PP (IN of)
            (NP (DT the) (NN disease))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Her) (NN cousin))
      (VP
        (VP (VBD underwent)
          (NP
            (NP (NN lumpectomy))
            (VP (VBN followed)
              (PP (IN by)
                (NP
                  (NP (NN chemotherapy))
                  (, ,)
                  (NP (NN radiotherapy)))))))
        (CC and)
        (VP (VBZ is)
          (ADVP (RB presently))
          (PP (IN on)
            (NP (NN tamoxifen))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Her) (NN mother))
      (VP (VBD had)
        (NP (NN breast) (NN cancer))
        (PP (IN in)
          (NP
            (NP (DT both) (NNS breasts))
            (, ,)
            (VP (VBN diagnosed)
              (PP (IN at)
                (NP (NNS ages) (CD 41)
                  (CC and)
                  (CD 42))))))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBN indicated)
              (PP (IN by)
                (NP (DT the)
                  (ADJP (RB completely) (VBN filled))
                  (NN symbol))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP She))
      (VP
        (VP (VBD underwent)
          (NP
            (NP (JJ bilateral) (NN mastectomy))
            (CC and)
            (NP
              (NP (NN hysterectomy))
              (VP (VBN followed)
                (PP (IN by)
                  (NP
                    (NP (NN chemotherapy))
                    (CC and)
                    (NP (NN radiotherapy))))))))
        (CC and)
        (VP (VBD died)
          (PP (IN of)
            (NP (DT the) (NN disease)))
          (PP (IN at)
            (NP (NN age) (CD 44))))))
    (. .)))

(
  (S
    (S
      (NP (DT A) (JJ second) (JJ maternal) (NN aunt))
      (VP (VBD was)
        (VP (VBN diagnosed)
          (PP (IN with)
            (NP
              (NP
                (NP
                  (NP (NN colon) (NN cancer))
                  (PP (IN at)
                    (NP (NN age) (CD 52))))
                (PRN (-LRB- -LRB-)
                  (NP (NN light) (JJ half-filled) (NN symbol))
                  (-RRB- -RRB-)))
              (CC and)
              (NP
                (NP
                  (NP (NN breast) (NN cancer))
                  (PP (IN at)
                    (NP (NN age) (CD 55))))
                (PRN (-LRB- -LRB-)
                  (NP (NN dark) (JJ half-filled) (NN symbol))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (PP (VBN Based)
        (PP (IN on)
          (NP
            (NP (DT this) (NN pattern))
            (PP (IN of)
              (NP (JJ familial) (NN cancer))))))
      (NP (DT the) (NN patient))
      (VP
        (VP (VBD was)
          (VP (VBN considered)
            (S
              (VP (TO to)
                (VP (VB be)
                  (PP (IN at)
                    (NP
                      (NP (JJ high) (NN risk))
                      (PP (IN of)
                        (S
                          (VP (VBG developing)
                            (NP (NN breast) (NN cancer))))))))))))
        (CC and)
        (VP (VBD was)
          (VP (VBD entered)
            (PP (IN into)
              (NP (DT the) (JJ low) (NN power) (NN MRI) (NN screening) (NN validation)
                (CC and)
                (NN feasibility) (NN study)))))))
    (. .)))

(
  (S
    (S
      (PP (VBG Following)
        (NP (PRP$ her) (NN diagnosis)))
      (, ,)
      (NP (PRP she))
      (VP (VBD was)
        (VP (VBN confirmed)
          (PP (IN as)
            (S
              (VP (VBG carrying)
                (NP
                  (NP (DT a) (NN Q1200X) (NN mutation))
                  (PP (IN in)
                    (NP (DT the) (NN BRCA1) (NN gene))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 2))
      (: :)
      (NP
        (NP (NN Ultrasound))
        (PP (IN of)
          (NP (DT the) (JJ MRI-detected) (NN lesion))))
      (. .))))

(
  (S
    (S
      (PP (VBG Following)
        (NP (NN MRI)))
      (, ,)
      (NP (DT the) (NN patient))
      (VP (VBD was)
        (VP (VBN scheduled)
          (PP (IN for)
            (NP (NN ultrasound)))
          (S
            (VP (TO to)
              (VP (VB identify)
                (NP
                  (NP (DT the) (JJ questionable) (NNS lesions))
                  (VP (VBN seen)
                    (PP (IN on)
                      (NP (NN MRI)))
                    (PP (IN for)
                      (NP (JJ possible) (NN core) (NN biopsy)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN Under)
        (NP (NN ultrasound)))
      (NP
        (NP (DT the) (NN lesion))
        (PP (IN of)
          (NP (NN concern))))
      (VP (VBD was)
        (VP
          (VP (VBN identified))
          (CC and)
          (VP (VBN biopsied)
            (PP (IN at)
              (NP (DT the) (CD 1:00) (NN location)))
            (PP (IN in)
              (NP (DT the) (JJ left) (NN breast)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Additionally))
      (, ,)
      (NP
        (NP (CD one) (NN lesion))
        (VP (VBN seen)
          (PP (IN by)
            (NP (NN MRI)))
          (PP (IN in)
            (NP
              (NP (DT the) (JJ right) (NN breast))
              (PP (IN at)
                (NP (DT the) (NN 4:00) (NN location)))))))
      (VP (VBD was)
        (VP
          (VP (VBN identified))
          (CC and)
          (VP (VBN biopsied)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 3))
      (: :)
      (NP
        (NP (NNS Micrographs))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ non-diseased) (JJ primary) (JJ human) (JJ mammary) (NN epithelial) (NNS cultures))
            (PRN (-LRB- -LRB-)
              (NP (NNS HMEC))
              (-RRB- -RRB-))))
        (PP (IN from)
          (NP (DT the) (NN BRCA1) (NN mutation) (NN carrier))))
      (. .))))

(
  (S
    (NP
      (NP
        (ADJP (NN A) (-RRB- -RRB-) (JJ Contralateral))
        (NN breast))
      (: –)
      (S
        (NP
          (NP (DT A) (NN cluster))
          (PP (IN of)
            (NP
              (NP (JJ epithelial) (NNS cells))
              (VP (VBN called)
                (S
                  (NP (DT a) (NN mammosphere)))))))
        (VP (VBZ is)
          (VP (VBN shown)
            (PP (IN on)
              (NP
                (NP (DT the) (JJ left) (NN center))
                (PP (IN of)
                  (NP (DT the) (NN image) (NN sitting)))
                (PP (IN on)
                  (NP
                    (NP (DT a) (NN field))
                    (PP (IN of)
                      (NP (NNS fibroblasts))))))))))
      (. .))))

(
  (S
    (NP
      (NP
        (ADJP (NN B) (-RRB- -RRB-) (JJ Ipsilateral))
        (NN breast))
      (: –)
      (S
        (NP
          (NP (DT The) (JJ original) (JJ fresh) (NN tissue) (NN block))
          (SBAR
            (WHPP (IN from)
              (WHNP (WDT which)))
            (S
              (NP (DT this) (NN culture))
              (VP (VBD was)
                (VP (VBN derived))))))
        (VP (VBD was)
          (VP (JJ located)
            (NP (CD 4) (NN cm))
            (PP (IN from)
              (NP (DT the) (JJ infiltrating) (JJ ductal) (NN carcinoma))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (DT The) (NN structure))
        (VP (VBN shown)))
      (VP (VBZ is)
        (NP
          (NP (DT a) (NN cluster))
          (PP (IN of)
            (NP
              (NP (JJ rounded) (JJ epithelial) (NNS cells))
              (VP (VBG manifesting)
                (NP
                  (NP (DT a) (NN column) (NN configuration))
                  (VP (VBN called)
                    (S (`` ``)
                      (NP (JJ pre-ductal) (NN linearization) (NN '')))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT Both) (NNS images))
      (VP (VBD were)
        (VP (VBN captured)
          (PP (IN under)
            (NP
              (NP (JJ Differential) (NN Interference) (NN Contrast) (-LRB- -LRB-) (JJ DIC) (-RRB- -RRB-) (NNS optics))
              (PP (IN on)
                (NP
                  (NP (DT a)
                    (NP (NNP Zeiss) (NNP Axiovert) (CD 100))
                    (NN microscope))
                  (PP (IN at)
                    (NP
                      (NP (DT a) (NN total))
                      (PP (IN of)
                        (NP (CD 140x) (NN magnification))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 4))
      (: :)
      (NP
        (NP (NN Comparison))
        (PP (IN of)
          (NP
            (NP (DT the) (NN NER) (NN capacity))
            (PP (IN of)
              (NP
                (NP (DT a) (NN PBL) (NN sample))
                (PP (IN from)
                  (NP
                    (NP (PRP$ our) (NN BRCA1) (NN mutation) (NN carrier) (NN patient))
                    (PP (IN with)
                      (NP
                        (NP (DT those))
                        (PP (IN of)
                          (NP
                            (NP (DT a) (NN population))
                            (PP (IN of)
                              (NP (JJ disease-free) (NNS controls))))))))))))))
      (. .))))

(
  (S
    (NP (DT The) (NN dark) (NN horizontal) (NN line))
    (VP (VBZ indicates)
      (NP
        (NP (DT the) (NN average))
        (PP (IN for)
          (NP (DT the) (JJ normal) (NN population))))
      (, ,)
      (SBAR (IN while)
        (S
          (NP (DT the) (JJ dotted) (NNS lines))
          (VP (VBP indicate)
            (NP
              (NP (JJ upper) (NNS limits))
              (PP (IN for)
                (NP
                  (NP (JJ residual) (NN NER) (NN activity))
                  (PP (IN in)
                    (NP
                      (NP (NNS patients))
                      (PP (IN with)
                        (NP
                          (NP
                            (NP (DT the) (JJ hereditary) (NN NER) (NN deficiency))
                            (NN disease) (NN XP) (-LRB- -LRB-) (CD 0.50) (-RRB- -RRB-))
                          (CC and)
                          (NP
                            (NP (DT the) (JJ cut-off))
                            (VP (VBN established)
                              (PP (IN in)
                                (NP (PRP$ our) (NN breast) (NN tissue) (NN study)))))))))))
              (SBAR
                (WHNP (WDT that))
                (S
                  (VP (VBD identified)
                    (NP
                      (NP (NNS tumors))
                      (PP (IN with)
                        (NP
                          (NP (JJ high) (NN sensitivity))
                          (CC and)
                          (NP (NN specificity) (-LRB- -LRB-) (CD 0.70) (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 5))
      (: :)
      (NP
        (NP (NN Comparison))
        (PP (IN of)
          (NP
            (NP (DT the) (NN NER) (NNS capacities))
            (PP (IN of)
              (NP
                (NP (CD two) (NNS samples))
                (PP (IN of)
                  (NP (JJ normal) (NN breast) (NN epithelium)))
                (PP (IN from)
                  (NP
                    (NP (PRP$ our) (NN BRCA1) (NN mutation) (NN carrier) (NN patient))
                    (PP (IN with)
                      (NP
                        (NP (DT those))
                        (PP (IN of)
                          (NP
                            (NP (DT a) (NN population))
                            (PP (IN of)
                              (NP
                                (NP (JJ disease-free) (NNS controls))
                                (SBAR
                                  (WHNP (WP who))
                                  (S
                                    (VP (VBD underwent)
                                      (NP (NN breast) (NN reduction) (CD mammoplasty))))))))))))))))))
      (. .))))

(
  (S
    (S
      (NP (DT The) (NN dark) (NN horizontal) (NN line))
      (VP (VBZ indicates)
        (NP
          (NP (DT the) (NN average))
          (PP (IN for)
            (NP
              (NP (DT the) (JJ normal) (NN population))
              (PP (IN of)
                (NP
                  (NP (NN breast) (NN reduction) (NN epithelium))
                  (PRN (-LRB- -LRB-)
                    (NP (NN BRE))
                    (-RRB- -RRB-)))))))))
    (, ,) (IN while)
    (S
      (NP (DT the) (JJ dotted) (NNS lines))
      (VP (VBP indicate)
        (NP
          (NP (JJ upper) (NNS limits))
          (PP (IN for)
            (NP
              (NP (JJ residual) (NN NER) (NN activity))
              (PP (IN in)
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP
                      (NP
                        (NP (DT the) (JJ hereditary) (NN NER) (NN deficiency))
                        (NN disease) (NN XP) (-LRB- -LRB-) (CD 0.50) (-RRB- -RRB-))
                      (CC and)
                      (NP
                        (NP (DT the) (JJ cut-off))
                        (VP (VBN established)
                          (PP (IN in)
                            (NP (PRP$ our) (NN breast) (NN tissue) (NN study)))))))))))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBD identified)
                (NP (NNS tumors))
                (PP (IN with)
                  (NP
                    (NP (JJ high) (NN sensitivity))
                    (CC and)
                    (NP (NN specificity) (-LRB- -LRB-) (CD 0.70) (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN patient) (NN sample))
        (PP (IN on)
          (NP (DT the) (JJ left))))
      (VP (VBD was)
        (VP (VBN derived)
          (PP (IN from)
            (NP (DT the) (JJ ipsilateral) (-LRB- -LRB-) (JJ left) (-RRB- -RRB-) (NN breast))))
        (, ,)
        (SBAR (IN while)
          (S
            (NP
              (NP (DT the) (NN sample))
              (PP (IN on)
                (NP (DT the) (JJ right))))
            (VP (VBD was)
              (PP (IN from)
                (NP (DT the) (JJ contralateral) (-LRB- -LRB-) (JJ right) (-RRB- -RRB-) (NN breast))))))))
    (. .)))

